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Chronic infection of hepatitis B vims (HBV) is an important health issue 
worldwide as there are over 350 million infected patients in the world. These 
chronic carriers are at high risks in developing liver cirrhosis or hepatocellular 
carcinoma (HCC). Therefore, a case-control study of 100 HBV-related HCC patients 
and 100 patients chronically infected with HBV, all recruited from Prince of Wales 
Hospital, was carried out to identify genomic markers of HBV. The HBV sequences 
from these patients belonged to either genotype B, Ce or Cs. Markers were 
identified in each of the group. These markers might help in predicting the potential 
risk of HCC development. 
Although the markers have diagnostic purposes, their functional properties 
await further study. Some of them are clustered at the promoter regions, namely 
pre-Sl promoter and X promoter/enhancer I (X pro/enhl) of genotype B and core 
promoter/enhancer II (core pro/enhll) of genotype Cs. In my project, 
Dual-Luciferase Reporter Assay was used to study the effect of these markers. HBV 
promoters from chronic hepatitis B patients and most similar to the consensus 
sequence of the corresponding genotype were cloned. Variants were made by 
site-directed mutagenesis. Control and mutant clones from HCC patients were also 
constructed to study in parallel with the pairs from chronic carriers. Results of 
viii 
reporter assay showed that mutations on pre-Sl promoter and X pro/enhl did not 
confer any change to the promoter activity. On the contrary, the mutation on core 
pro/enhll mutant conferred a 58% increase in promoter activity. In agreement, a 
drastic decrease was observed when the point mutation on core pro/enhll derived 
from HCC was mutated back to wild-type. An infectious HBV clone would therefore 
be needed for further functional analysis of the marker on core pro/enhll. A 
replication-competent full-length HBV genome clone had been obtained as shown 
by Southern blot hybridization. However, due to technical problems in application, 
the clone was reconstructed into a 1.3-fold HBV genome clone. HBeAg and HBsAg 
were detectable in the supernatant after transfection, and the replication competency 
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Introduction 
CHAPTER 1 INTRODUCTION 
1.1 Pathogenesis of HBV Infection 
HBV infection is a global health issue, as according to the latest report of World 
Health Organization in 2000，two billion people have HBV infection, of which more 
than 350 million people are chronically infected. HBV may result in acute 
self-limited hepatitis, fulminant hepatitis and chronic hepatitis. Most primary 
infections in adults are acute self-limited. This type of infection is transient, with 
clearance of virus from blood and liver eventually and the development of immunity 
to reinfection (Ganem and Prince, 2004). Fulminant hepatitis is also a kind of 
transient infection, but it is rare and can lead to liver failure. The mortality of this 
infection is high and liver transplantation is required. When the host immune 
response cannot eradicate the vims, HBV infection becomes chronic infection (Lai 
and Locamini，2002). The likelihood that a person develops chronic infection is 
age-dependent, with more than 90% of infants infected with HBV develop into 
chronic hepatitis (Hyams, 1995). Chronic hepatitis can lead to cirrhosis and HCC. 
The risk for chronically HBV infected patients to develop HCC is 100 times as high 
as that of non-carriers (Ganem and Prince, 2004). For this reason, patients with 
chronic hepatitis should receive medical evaluation regularly. 
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1.2 Classification and Structure 
HBV is the prototype member of the Hepadnaviridae, a family of DNA viruses 
having strong preference for infecting liver cells (Ganem and Prince, 2004). They 
are the smallest DNA viruses currently known. All hepadnaviruses are highly 
species specific and only infect a limited range of hosts. This family has been 
divided into two groups: the mammalian viruses and the avian viruses. The HBV in 
our study only infects human and some other primates (Kidd-Ljunggren et al.’ 
2002). 
Infectious HBV virion (also known as Dane particle) has a diameter of 40 - 42 
nm with a double-shelled structure. Its structure is illustrated in Fig. 1.1. It is formed 
by the outer envelope and the inner icosahedral nucleocapsid (or core). The envelope 
contains hepatitis B surface antigens (HBsAg) with small amount of lipids whereas 
the nucleocapsid contains core proteins. Enclosed by the nucleocapsid is a DNA 
genome with partially double-stranded relaxed circular structure, which is covalently 




Icosahedral Small surface antigen (SHB) 
UC eocaps—� . —Middle surface antigen (MHB) 
• ~ Large surface antigen mSJMlir 
^ ~ ~ P a r t i a l l y double-stranded 
Polymerase 
Adapted from Perkins, 2002 
http ://www. rit. edu/~j^faa/infectious.htnil 
Fig. 1.1 Schematic illustration of the structure of HBV. The outer layer 
is the envelope made up of surface antigens. Inner layer is the 
nucleocapsid made up of core proteins, which comprises the partially 
double-stranded DNA covalently linked to the viral polymerase. 
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1.3 HBV Genome 
The genome of HBV is a partially-double stranded 3.2 kb DNA (Fig. 1.2). It 
consists of a long minus-strand DNA with terminal redundancy of about 7-9 bases. 
The minus-strand DNA is not a closed circular structure because the 5' end of it is 
covalently linked to the N-terminal portion of the viral polymerase. On the other 
hand, the plus-strand DNA bridges the discontinuity between the 5' and the 3' ends 
of minus-strand DNA keeping the HBV DNA structure circular, but leaving a huge 
gap at the 3’ end. The genomic organization of HBV is very compact as it consists of 
four partially overlapping open reading frames (ORFs). They are P, preS/S, preC/C 
and X which encode for polymerase, surface protein, core protein and HBx protein, 
respectively. In fact, the preS/S region is divided into the pre-Sl region, pre-S2 
region and S region by three in-frame initiation codons. They allow differential 
initiation of three different surface antigens including large hepatitis B surface 
antigens (LHBs), middle hepatitis B surface antigens (MHBs), and small hepatitis B 
surface antigens (SHBs). SHB is also known as HBsAg in the clinical tests. The 
preC/C region has two in-frame initiation codons which enable the expression of 
core protein and a longer protein form, the precursor of hepatitis B e antigen 
(HBeAg). The precursor undergoes proteolytic cleavage en route the secretory 
pathway to become mature HBeAg, which can be detected in blood. It plays no role 
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in viral assembly and its function remains unclear (Lai and Locamini, 2002; Parekh 
et al., 2003; Ganem and Prince, 2004). HBeAg and HBsAg are among the serologic 
markers for HBV infection. 
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P r e S 2 / S 
iUf^m 
§ 4 f h ^ H i 11 
卞 Key 
O Enhancer I & X promoter 
Adapted from Moolla a i , 2002 二 Negative regulatory element 
^ Pre-S2/2 promoter 
Q Pre-Sl promoter 
• Polyadenylation signal 
pv Enhancer II & 
^ core promoter 
Fig. 1.2 Genome organization, regulatory elements and viral mRNAs. The 
plus- and minus-strand DNAs are depicted in the centre. The numbering 
starts at the EcoRl site, and is indicated by a short arrow. The cis elements 
are depicted as circular and rectangular boxes. Four overlapping ORFs are 
shown as arrows with initiation codons. The outer region depicts the viral 
mRNAs. The black triangles represent the 5’ ends of mRNAs. 
Heterogeneous transcription initiation sites on precore mRNA and pre-S2/S 
are shown by multiple triangles. All the viral mRNAs have a common 3' 
end, which is depicted as blue box in the figure. 
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1.4 Replication Cycle 
The cardinal feature of the hepadnavirus replication cycle is the involvement of 
reverse transcription of a 3.5 kb pregenomic RNA (pgRNA). The infectious virions 
bind to the target cells through an as yet unknown receptor. The nucleocapsid is 
released into the cytoplasm and directs the partially double-stranded HBV genome 
to the nucleus, where the genomes are repaired to form a covalently closed circular 
DNA (cccDNA). This cccDNA serves as the transcriptional template ofpgRNA, and 
other viral mRNAs which are translated in the cytoplasm. There, viral nucleocapsids 
are assembled from core proteins with pgRNA, which is encapsidated by the viral 
polymerase, packaged inside. This pgRNA is first reverse transcribed into 
minus-strand DNA, which subsequently serves as template for the synthesis of 
plus-strand DNA, all mediated by the viral polymerase. The resulting cores either 
bud into the endoplasmic reticulum, where it is enveloped by the surface antigens 
and secreted into the blood, or recycle the relaxed-circular DNA back into nucleus to 
form pool of cccDNA. Non-infectious subviral particles, in spheres of filamentous, 
are secreted in excess compared to the virions (Lai and Locamini, 2002; Ganem and 
Prince, 2004). The replication cycle is shown in Fig. 1.3. 
7 
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Infectious Non-infectious subvirial particles 
HBV virion ^ ^ ^ ^ ^ (sphere and filamentous) 
。 一 V ^ ^ T # \ 
ooo V V ^ fc 3 ^ § 8 
/ ^ ^ 广 
Receptor X / 
^ ^ Golgi 
i M L ^ ^ J ^ ^ 
ER/IC i ^ ^ DNA 
• y T \ synthesis 
广 Assembly of ^ T ^ 
i \ nucleocapsid ^ ^ r 
f o o o \ ^ ^ ^ 
I / cccDNA I K 
\ ^ / f � e Q ) 
\ Genomic & J proteins ^ ^ ^ 
\ subgenomic J O f / 
乂 匪 s ^ ^ . H B s A g \ / 
V • H B e A g 3 .5kbpgRNA J Adapted from Lai & Locamini, 2002 
Fig. 1.3 Summary of HBV replication cycle. cccDNA, covalently 
closed circular DNA; pgRNA, pregenomic RNA; pol, polymerase; S, 
small surface antigen; M, middle surface antigen; L, large surface 
antigen; ER, endoplasmic reticulum; IC, intermediate compartment. 
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1.5 HBV Genotypes and Nomenclature 
1.5.1 Asian prevalent genotypes 
HBV is divided into eight genotypes designated as A to H, which is based on 
greater than 8% nucleotide heterogeneity over the entire genome (Bartholomeusz 
and Schaefer，2004). The prevalence of different HBV genotypes depends on 
geographical locations. In Asia, genotypes B and C are the most prevalent (Kao et 
al, 2000; Orito et al., 2001). Some genotypes can be further divided into subgroups, 
which are identified on the basis of a more than 4% (but less than 8%) difference 
over the complete HBV genome. Recent report has suggested that HBV genotype C 
can be further divided into two subgroups, Ce and Cs (Chan et al., 2005). Ce is more 
prevalent in Far East (Korea and Japan) and northern China whereas Cs is more 
prevalent in Southeast Asia, including Vietnam, Thailand, Malaysia, and southern 
China. 
1.5.2 Numbering system 
Different genotypes have different genomic lengths. Both genotypes B and D are 
3215 nucleotides in length. Due to the circular structure of HBV, a reference point 
has to be chosen for numbering the nucleotide position. The EcoRl site is chosen 
and the first T has been designated as the first nucleotide. The numbering of HBV 
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1.6 Identification of Markers in HBV Genome for 
HCC development 
In Southeast Asia, where chronic infection of HBV is endemic (Bowyer and Sim, 
2000; Alestig et al.，2001; Sugauchi et aL, 2002), the problem of HCC development 
is serious. According to Department of Health, HCC ranked third in 2003 among the 
fatal cancers in Hong Kong. Until now, there is a lack of curative treatment of HCC 
and only early detection can enhance survival (Yuen et al.’ 2000). Identification of 
risk factors for HCC can help to stratify patient risk, thus play an important role in 
cancer surveillance program and effective public health resource allocation. HBV 
genotype is one of the factors that have been identified. Several reports have 
suggested that in Asia, HBV genotype C is associated with a higher risk of HCC 
than genotype B (Kao et al” 2000; Onto et al., 2001). However, up to date, no viral 
marker(s) has been identified. Therefore a case-control study was therefore launched 
by Chan et al (unpublished data) to identify markers in the HBV genome for HCC 
development. 
In the study, 100 patients with HBV-related HCC were compared with 100 
patients who had been chronically infected with HBV. The two groups of patients 
were age- and gender- matched and were all recruited from the Hepatology Clinic in 
Prince of Wales Hospital of The Chinese University of Hong Kong. The HBV DNA 
11 
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was extracted from serum of the patients, followed by sequencing of the complete 
genome. It was found that all HBV DNA sequences belonged to either genotypes B， 
Ce or Cs. By data-mining techniques, several hot spot mutations in the HBV 
genome were identified as markers in each of the genotype. 
12 
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1.7 Pro j ect Obj ective 
Although the markers have diagnostic purposes, their functional properties 
remain unclear. Some of them were found to cluster at the promoter regions, 
including mutation at nucleotide 2712 from T to C (T2712C) in pre-S 1 promoter, 
mutation at nucleotide 1165 from C to T (C1165T) in X pro/enhl and mutation at 
nucleotide 1613 from G to A (G1613A) at core pro/enhll. The first two mutations 
were identified as markers of HBV genotype B whereas the last one was marker of 
HBV genotype Cs. The aim of my project was to study the effect of these mutations 
on promoter activity using the dual-luciferase reporter assay and to construct a 
replication competent HBV construct for future functional analysis of the mutations. 
In long term, this study might help in the understanding of HCC development, 




1.8 Promoters of HBV 
1.8.1 Pre-Sl promoter 
Four promoters and two enhancers have been identified in HBV genome. Pre-Sl 
promoter is located in the preS/S region, 5' to the pre-Sl region. It controls the 
transcription of the LHBs mRNA with 2.4 kb in length (Fig. 1.2). This element is the 
only HBV promoter that contains a classical TATA-box sequence (Moolla et al, 
2002), and therefore only LHBs mRNA has a defined 5'end. A binding site for the 
liver-specific transcription factor, HNF-1, is located upstream of the TATA-binding 
protein motif, and basic transcriptional activity of the SI promoter requires the 
presence of these two elements (Raney et al., 1994). It also contains binding site for 
another liver-specific transcription factor, HNF-3, which can increase the production 
of2.4kb mRNA (Fig. 1.2). 
1.8.2 Xpromoter and enhancer I 
The X promoter controls the transcription of the small 0.9 kb mRNA sequence 
which encodes HBx protein (Zheng et al., 1994). It is about 140 nucleotides 
upstream of the transcription initiation site. The X promoter lacks the classical 
TATA-box, but it contains binding sites of ubiquitous and liver-specific 
transcription factors such as the regulatory protein termed X-promoter binding 
14 
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protein (Fukai et al., 1997). This regulatory sequence overlaps with one of the two 
enhancers, enhancer L It is a major enhancer in HBV genome and stimulates 
transcription of all mRNAs (Lai and Locamini, 2002). Its stimulating effect on 
promoter requires binding of both ubiquitous and liver-specific transcription factors, 
thus the effect is lower in non-hepatic cells. 
1.8.3 Core promoter and enhancer II 
The core promoter consists of a basal core promoter (BCP) and an upstream 
regulatory sequence. BCP is defined as the region consisting of cw-acting element 
which directs the initiation of pgRNA and precore mRNA (Moolla et al., 2002), 
both are 3.5 kb in length. The 5' end of pgRNA is downstream of the precore 
initiation codon, and therefore can only be translated into core protein, instead of the 
precore protein (Fig. 1.2). It also codes for the viral polymerase. Apart from 
encoding structural proteins, the pgRNA itself serves as a template for reverse 
transcription in the HBV replication cycle. The polymerase recognizes the stem-loop 
structure at the 5' end of pgRNA and hence mediates the encapsidation process of 
pgRNA onto nucleocapsid. The 5' end of precore mRNA is located upstream of the 
precore region. Multiple start sites have been detected (Fig. 1.2)，which may be 
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explained by the lack of a canonical TATA box within the BCP. The precore mRNA 
encodes for a precore protein, which is longer than the core protein by 29 amino 
acids at the N-terminal (the precore region). The first 19 residues of the 29 amino 
acids are cleaved by the signal peptidase in the endoplasmic reticulum. The 
C-terminal DNA-binding sequence of the truncated protein is cleaved subsequently 
in the Golgi compartment to yield the final product, HBeAg (Lai and Locamini, 
2002; Ganem and Prince, 2004). The translational initiation from the precore start 
codon is efficient, thus preventing the core protein expression from precore mRNA. 
Upstream of BCP are cis elements that can positively or negatively regulate the 
promoter activity. Furthermore, the core promoter overlaps with enhancer 11. It 
activates transcriptional activity of preS2/S promoter, the BCP and the X promoter. 
Its stimulating effect on promoter is more liver-specific than enhancer I (Zuckerman 
and Thomas, 1998). This region, core promoter together with enhancer II，is denoted 
as core pro/enhll in this study. Similar to pre-Sl promoter, core pro/enhll requires 
the binding of liver-enriched transcription factors such as HNF-4, HNF-3 and 
C/EBP. In regard of this, well-differentiated human hepatoma cell line, Huh-7, was 
chosen for the study. 
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1.8.4 Pair of mutations at BCP 
A pair of mutations, which is a change from A to T at nucleotide 1762 (A1762T) 
and from G to A at nucleotide 1764(G1764A), was first described in the BCP of 
HBV derived from Japanese patients (Okamoto et al., 1994; Sato et al” 1995). They 
are often present in patients with chronic active hepatitis and HCC, but rarely in 
asymptomatic carriers (Gunther et al., 1998; Baptista et al.’ 1999; Kao et al” 2003). 
The BCP mutation has been the focus of study and is known to suppress HBeAg 
expression (Buckwold et al., 1996; Hunt et al., 2000). 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Construction of pGL3-promoter Plasmids 
Construct pACore was a generous gift from Dr. Angeline Bartholomeusz of 
Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Australia. 
It contained a wild-type core pro/enhll from a HBV genotype A isolate. Other 
promoter clones were generated from HBV isolates extracted from patients' serum. 
2.1.1 Template selection 
HBV consensus sequence was given by the research team which involved in the 
project of HBV genomic marker. It was obtained by aligning multiple 
patients-derived HBV isolates of the same genotype and setting the consensus 
threshold for each nucleotide at 80%. It was then used as the reference sequence in 
the selection of template. Promoter regions of the HBV isolates were compared to 
that of the consensus sequence using a genetic analysis tool, MEGA 3.1, and the one 
with greatest homology to the consensus was chosen as template for polymerase 
chain reaction (PCR) amplification. Two HBV templates were chosen for each type 
of promoter studied. One was derived from chronic carrier while the other was from 
patient with HCC. 
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2.1.2 Amplification of promoters 
The promoters were amplified from the chosen HBV templates by PCR using 
the appropriate sets of primers (Tables 2.1 & 2.2). The reaction included 0.2 mM 
dNTP, 0.2 /xM each of forward and reverse primers, 5 /xl of extracted HBV DNA, 
0.25 /xl Advantage™ cDNA polymerase (Clontech Laboratories, Inc.) plus 0.25 jx\ of 
Pfu DNA polymerase (Promega) and IX Advantage'^^ cDNA polymerase PCR 
buffer (Clontech) in a total volume of 50 fxl The PCR was performed in a 3-minute 
(min) initial denaturation at 94°C，followed by 15 cycles of amplification (94°C for 
36 seconds (s), 55°C for 45 s and 68°C for 50 s) and a final extension at 68°C for 10 
min. Afterwards, 2 /xl of the PCR product was re-amplified in a reaction volume of 
50 jLtl with components same as above except for the buffer and DNA polymerase, 
which were changed to IX Pfu DNA polymerase buffer (Promega) and 0.5 /xl of Pfu 
DNA polymerase (Promega). The PCR was performed in a 3-min initial 
denaturation at 94°C，followed by 30 cycles of amplification (94°C for 36 s, 55°C 
for 45 s and 72°C for 50 s) and a final extension at 72°C for 10 min. The entire PCR 
product of each reaction was separated on a 1% Tris-acetate-EDTA (TAE) agarose 
gel. The DNA fragments with correct sizes were identified under the UVIPhoto gel 
documentation system (UVITec) and then purified using the QIAquick Gel 
Extraction Kit (Qiagen). 
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Table 2.1 Sets o f primers used for PCR amplification of H B V promoters 
Template Genotypes Promoters amplified Primers used 
CCl B X pro/ehni P 1 & P 2 
HI B X pro/ehnI P 1 & P 3 
CC2 B preSl promoter P 4 & P 5 
CC3 Cs core pro/enhll P6 & P7 
H3 Cs core pro/enhll P6 & P7 
Table 2 .2 Sequence and position of primers 
Name Sequence (5'to 3') Position Direction 
PI GGCTCGAGGGAAAGTATGTCAACGAATTGTGGG 980-1004 sense Xho\ 
P2 GCAAGCTTGGAAATGATGTATACTTGCGGG 1352-1373 antisense HindlW 
P3 GCAAGCTTGGGAATGATGTATACTTGCGGG 1352-1373 antisense HindlW 
P4 CCCTCGAGCCAGAGTATGTAGTTAATC 2706-2724 sense Xho\ 
P5 CACTAAGCTTTCCCCATGCCTITTCGAGG 2887-2869 antisense Hmd[\\ 
P6 CCCTCGAGCCGTGTGCACTTCGCTTC 1575 -1592 sense Xhol 
P7 ACTTAAGCTTGGTGCTGGTGAACAGACC 1813 -1796 antisense Himi[\\ 
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2.1.3 Cloning into pGL3-basic vector 
The entire purified PGR products were cleaved by 0.5 jitl each of Xhol and 
HindlU (Amersham Biosciences) in IX K buffer. The mixtures were incubated at 37 
�C for 4 hours (hr) followed by enzyme inactivation at 85°C for 15 min. Two 
microlitres of pGL3-basic vector was digested under the same conditions. After 
purification, 15.5 of digested PCR products were ligated into 2 /xl of pGL3-basic 
vector with 0.5 jul of T4 DNA ligase (New England Biolabs) in IX T4 DNA ligation 
buffer in a total reaction volume of 20 fil The reaction mixture was incubated at 4°C 
overnight. Whole ligation product was transformed into competent DH5a cells, with 
a heat-shock time of 90 s. Transformants were selected on Lurin-Bertani-ampicillin 
) 
(LBA) agar plate at 37�C for 16 hr. 
2.1.4 Screening and pi as mid preparation 
Colony PCR was performed to screen the insert. It was achieved by suspending a 
single colony in PCR reaction mix, which included 0.2 /xM each of the vector 
primers, RVprimerS (5’ CTAGCAAAATAGGCTGTCCC 3，）and GLprimer2 (5， 
CTTTATGTTTTTGGCGTC TTCC 3，)，0.2 mM dNTP, 0.1 /xl of Taq polymerase 
(Amerhsam), IX PCR buffer (Clontech) in a total reaction volume of 25 /xl. The 
PCR was performed with a 5-min denaturation at 94°C, followed by 35 cycles of 
21 
Materials and Methods 
amplification (94°C for 36 s，55°C for 45 s，72°C for 50 s) and a final extension at 
72°C for 10 min. The PCR products were run on a 1% TAB agarose gel. The one 
which had band with correct size indicated the presence of insert and its 
corresponding colony was picked for plasmid preparation. Each of the selected 
colonies was inoculated in 3 ml of LB A media at 37°C with shaking at 250 rpm for 
16 hr. The plasmids were purified from the colonies by the Rapid Plasmid 
Purification System (Marligen Bioscences). Nucleotide sequencing of the cloned 
plasmids was performed by Tech Dragon Limited with RVprimer3 and GLprimer2 
for further confirmation. Plasmids with correct sequences were prepared in 
large-scale by HiSpeed™ Plasmid Midi Kit (Qiagen). The clones eventually 
obtained were named as pCoreC, pCoreH, pPreSl, pXC and pXH, which 
corresponded to templates CCl, HI, CC2, CC3 and H3 respectively. 
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12 Construction of Mutant Promoter Clones 
2.2.1 Site-directed mutagenesis 
pCoreC/1613A, pCoreH/1613Q pXC/1165T, pXH/1165C and pACoreM were 
mutant clones derived from pCoreC, pCoreH, pXC，pXH and pACore respectively. 
Moreover, pCoreC-wtBCP and pl613A-wtBCP were generated respectively from 
pCoreC and pCoreC/1613A. Mutations were introduced by PCR-based site-directed 
mutagenesis. Primers bearing the target mutation sites (shown as red characters in 
Table 2.4) were designed. By using the appropriate pair of primers, two fragments 
were generated from each pGL3-promoter clone (Table 2.3). The reaction included 
0.2 mM dNTP, 0.2 juM each of forward and reverse primers, 2 jLtl of pGL3-promoter 
clones (50-fold dilution of DNA purified by Rapid Plasmid Purification System) and 
0.5 jLtl of Pfu DNA polymerase in IX Pfu DNA polymerase PCR buffer (Promega) in 
a total volume of 50 /il. The PCR was performed with a 3-min initial denaturation at 
94°C，followed by 33 cycles of amplification (94�C for 36 s, 55°C for 45 s and 72°C 
for 50 s)，and a final extension at 72°C for 10 min. Those 2 fragments were then 
purified and linked together by second round of PCR. The reaction started with the 
above components and 2 jxl each of the 2 fragments in a total volume of 50 /xl 
without any primer. It was performed with a 3-min denaturation at 94°C，followed 
by 10 cycles of amplification (94�C for 36 s, 55°C for 45 s and 72°C for 50 s) and a 
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final extension at 72°C for 10 min. During this extension period, 0.5 jitl each of 
RVprimer3 and GL primer2 were added. PGR then resumed for 20 more cycles. 
After purification, the fragments were digested by Xhol and HindlU and cloned into 
pGL3-basic vectors as previously described. 
2.2.2 pPreSl/2 712C mutant clone 
The case for pPreSl was much easier as the target mutation site was located near 
the 5' end of the promoter. pPreSl/2712C was obtained by PCR using a new forward 
primer P18 (5' CCCTCGAGCCAGAGCATGTAGTTAATC 3，，bold character is the 
mutation, underlined is the Xhol restriction site, nucleotide position from 2706-2724) 
bearing the mutation site at nucleotide 2712 with a T to C exchange and the reverse 
primer GLprimer2. 
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Table 2.3 Sets of primers used for PCR amplification of 2 HBV 
fragments in site-directed mutagenesis 
„ , Primers used for Primers used for Clones 
Fragment 1 Fragment 2 generated 
pXC RVprimer3 & P9 P8&GLprimer2 pXC/1165T 
pXH RVprimer3 &P11 PIO & GLprimer2 pXH/1165C 
pCoreC RVprimer3 &P13 P12 & GLprimer2 pCoreC/1613A 
pCoreH RVprimer3 & P15 P14 & GLprimer2 pCoreH/1613G 
pACore RVprimer3 & P17 P16 & GLprimer2 pACoreM 
pCoreC RVprimer3 &P19 P18 & GLprimer2 pCoreC-wtBCP 
pCoreC/1613A RVprimer3 & P19 P18 & GLprimer2 pl613A-wtBCP 
Table 2.4 Sequence, position and the mutation sites of primers 
Name Sequence (5'to 3') Position Direction Mutation 
P8 TCGGCAACGGTCTGGTCTGTGC 1155-1176 sense C1165T 
P9 GCACAGACCAGACCGTTGCCGA 1176-1155 antisense G1165A 
PIO TCGGCAACGGCCTGGTCTGTGC 1155-1176 sense T1165C 
P l l GCACAGACCAGGCCGTTGCCGA 1176-1155 antisense A1165G 
P12 CGTCGCATGGAAACCACCGTG 1602-1622 sense G1613A 
PI 3 CACGGTGGTTTCCATGCGACG 1622-1602 antisense C1613T 
P14 CGTCGCATGGAGACCACCGTG 1602-1622 sense A1613G 
P15 CACGGTGGTCTCCATGCGACG 1622-1602 antisense T1613C 
P16 GGGGGAGGAGATTAGGTTAATGATCTTT 1742-1769 sense A1762T/G1762A 
PI 7 CAAAGATCATTAACCTAATCTCCTCCCC 1770-1743 antisense T1762A/C1764T 
PI 8 TTGGGGGAGGAGACTAGATTAAAGGTCTT 1740-1768 sense T1762A/A1764G 
PI 9 ACAAAGACCTTTAATCTAGTCTCCTCCCCC 1771-1742 antisense A17621711764C 
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2.3 Cloning of Full-length HBV Genomes 
2.3.1 Replication-competent HB V clone 
Due to the lack of an efficient cell-culture system that can support natural 
infection of HBV, researchers can only rely on transfection when introducing HBV 
DNA into the cultured cells (Lai and Locamini, 2002). A replication-competent 
HBV clone is an important tool for functional analysis of the naturally occurring 
mutants. Any association between the mutations and HBV replication capacity, 
pgRNA transcription, HBeAg and HBsAg production can only be investigated with 
an infectious HBV clone, of which the replication can be detected in cell line. 
Because of the circular structure of HBV, replication-competent clone had to be 
constructed in tandem dimer arrangement, so as to ensure the integrity of each ORE 
However, Gunther et al. (1995) has reported a novel method in constructing a 
replication-competent HBV clone (Figs. 2.1 A and B), suggesting that a full-length 
HBV genome instead of tandem dimer could be used in transfection. Our method of 
cloning was based on it. In brief, the key of this method is a type II-S restriction 
enzyme, Sap\, which has spatially separate recognition and cleavage sites. HBV 
genome with compatible sticky ends can be generated after digestion without any 
addition of heterologous sequence. They suggested that once the linearized HBV is 
transfected, the cells will facilitate circularization of HBV and make it replicative. 
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A 
Y 
5' GCTCTTCNNNN 3' 







^ ^ ^ ^ t ^ i r c u l a r i z a t i o n ^ ^ ^ ^ 
Adapted from Gunther et al.，1995 ^ ^ ^ 
Fig. 2.1 The strategy of the method by Gunther et al. (1995). (A) The 
recognition and cleavage sites ofSapl. The recognition site is highlighted 
in red while the cleavage site is shown by the arrows. (B) The Sap\ site is 
incorporated in the plasmid (pUC), flanking the ends of the HBV 
sequence. The full-length HBV sequence is then excised from the plasmid 
by Sapl. After transfection, the linearized HBV will circularize in cells 
and be able to replicate. 
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2.3.2 Amplification offull-length HBV genomes 
HBV DNA extracted from patients serum samples were used as templates. 
Full-length HBV genomes of genotypes Ce and Cs were amplified. The PCR 
amplification was adapted from Gunther et al (1995). Each reaction was set up as 
follows: 0.2 liM each of forward and reverse primers, 4 /xl of DNA template, IX 
PicoMaxx® master mix (Stratagene) in a total volume of 50 fxl. The PCR was 
performed with primers HindUl-Sapl-F and Sacl-Sapl-R (Table 2.5) in a 2-min 
initial denaturation at 95°C, followed by 40 cycles of amplification (94°C for 40 s, 
cooling from 94°C to 60°C in 50 s, 60°C for 1 min, shifting from 60°C to 72°C in 
15s, 72°C for 4 min with an increment of 5 s/cycle in elongation). Five microlitres of 
PCR product was separated on a 1% TAE agarose gel and purified by 
GENECLEAN III kit® (Qbiogene) for cloning. 
2.3.3 Cloning into pUC19 vector 
The purified PCR products were cleaved by 0.5 jul of HindlW and 0.7 /xl of Sad 
in IX One-Phor-All® Buffer PLUS (OPA+) (all from Amersham Biosciences) in a 
total volume of 20 jitl. The mixtures were incubated at 37°C for 4 hr followed by 
enzyme inactivation at 85°C for 15 min. pUC19 vector was digested under the same 
conditions. The vector and insert were ligated, and then transformed into DH5a as 
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described in session 2.1.3. 
2.3.4 Screening for insert and sequence confirmation 
Colony PCR was performed with vector primers, M13U and M13R in a 5-min 
initial denaturation at 94°C, followed by 35 cycles of amplification (94°C for 36 s, 
55�C for 45 s，72°C for 3 min) and a final extension at 72�C for 10 min. PCR 
product of 3.2 kb was resulted for clones bearing the insert. Plasmids were prepared 
as described in session 2.1.4 and subject to sequencing. Primers used in screening 
and sequencing were listed in Tables 2.6 and 2.7. 
2.3.5 Excision of full-length HB Vfrom plasmid 
The full-length HBV genome was excised from recombinant plasmid before 
transfection. In each reaction, 2U//xg of Sapl was added in IX Buffer 4 (New 
England Biolabs) and incubated at 37°C for 16 hr. The digestion product was 
separated on 0.7% TAE agarose gel. A 3.2 kb fragment was purified. Numerous 
digestions were performed until substantial amount of DNA for each transfection 
was obtained, i.e. 5 /xg. 
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Table 2.5 Primers used for PCR amplification of full-length HBV genomes 
Name Sequence (5'to 3') Position Direction Restriction sites 
Hindm-Sapi-V CCGGAAAGCTTGCTCTTCTTT 1821-1841 sense HindWl 
TTCACCTCTGCCTAATCA Sap\ 
Sacl-Sapl-R\ CCGGAGAGCTCTTCAAAAA 1825-1806 antisense Underline -
GTTGCATGGTGCTGG Sapl 
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Table 2.6 Primers used in colony PCR 
Clone Primers used 
Full-length M13U, Core2ALT, 903, 1075，JM, 1798, Seq2, 2536, 
991-970, 3026, M13R 
HBV (nt 905-2000) M13U, 1460-1441，PC5, PC2, M13R 
HBV (nt 979-2617) M13U, 1460-1441, PCS, PC2, Core2ALT, M13R 
1.3-fold Cs clone M13U, 2076-2060, Core2ALT, 903, 1075’ JM, Seq2, 
2536, 970-991, M13R 
Table 2.7 Sequence and position of primers used in PCR amplification 
of HBV fragments and sequencing 
Name Sequence (5'to 3') Position Direction 
Seq2 TTGGCCAAAATTCGCAGTC 300-318 sense 
2536 CCCCACTGTTTGGCTTTCAG 715-734 sense 
970-991 GACATACTTTCCAATCAATAGG 970-991 sense 
3026 GCTGACGCAACCCCCACTGG 1186-1205 sense 
PC5 TCGCATGGAGACCACCGTGA 1607-1626 sense 
Core2ALT CTCCGGAACATTGTTCACCT 2031-2050 sense 
1075 AAGGTGGGAAACTTTACTGGGC 2469-2490 sense 
JM TTGGGGTGGAGCCCTCAGGCT 3037-3057 sense 
1460-1441 GGGTCGTCCGCGGGATTCAG 1460-1441 antisense 
PC2 GGCAAAAACGAGAGTAACTC 1959-1940 antisense 
2076-2060 ATAGCTTGCCTGAGTGC 2076-2060 antisense 
903 GTTGATAAGATAGGGGCATTTGGTGG 2325-2300 antisense 
1798 CCACTGCATGGCCTGAGGATG 3219-3199 antisense 
M13U GTAAAACGACGGCCAGT vector sense 
M13R CAGGAAACAGCTATGACC vector antisense 
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2.4 Re-construction into a 1.3-fold HBV Clone 
2.4.1 Cloning of HBV fragment from nucleotide 979-2617 (nt 979-2617) 
Full-length Cs clone prepared in midi-scale was diluted 100-fold as template. 
Two fragments were generated using the appropriate pairs of primers as shown in 
Table 2.8. Reaction was set up as follows: 0.2 fxM each of forward and reverse 
primers, 2 fil of diluted DNA template, IX PicoMaxx® master mix (Stratagene) in a 
total volume of 25 /A. The PCR was performed in a 3-min initial denaturation at 94 
�C，followed by 33 cycles of amplification (94°C for 36 s，55�C for 45 s，72V for 1 
min 30 s) and a final extension at 72°C for 10 min. After purification, the 2 
fragments were joined by a second round of PCR. The reaction was set up with 2 jul 
each of the fragments and IX PicoMaxx® master mix (Stratagene) in a total volume 
of 25 fil without any primer. It was performed with a 3-min initial denaturation at 94 
°C，followed by 10 cycles of amplification (94°C for 36 s，55�C for 45 s and 72°C 
for 2 min 30 s) and a final extension at 72°C for 10 min. During this extension 
period, 0.5 jul each of HindIII-980F and SacI-2617R were added. PCR then resumed 
for 24 more cycles plus a 10-min final extension at 72°C. The PCR product was 
cleaved by HindUl and Sad and cloned into pUC18 vector as described in session 
2.3.2. 
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2.4.2 Screening for insert and sequence confirmation 
Colony PCR was performed with vector primers, M13U and M13R. The PCR 
was performed with a 5-min initial denaturation at 94°C, followed by 35 cycles of 
amplification (94°C for 36 s, 55°C for 45 s，72°C for 2 min) and a final extension at 
72°C for 10 min. PCR product of 1703 bp was resulted for the right clones. Plasmids 
were prepared as described in session 2.1.4 and subject to sequencing (Tables 2.6 
and 2.7) 
2.4.3 Cloning ofHB Vfragment (nt 905-2000) 
HBV clone (nt 979-2617) prepared in small-scale was diluted 40-fold as 
template. Reaction was set up as follows: 0.2 jxM each of forward and reverse 
primers, 2 jLtl of diluted DNA template, IX PicoMaxx® master mix (Stratagene) in a 
total volume of 25 [xl The PCR was performed with primers 3026 and SacI-2000R 
(5，GCGAGCTCCGGTGTCGAGGA GATCACGAAT 3，’ underlined is the Sad 
restriction site, nucleotide position from 2587-2611, antisense) in a 3-min initial 
denaturation at 94°C，followed by 33 cycles of amplification (94°C for 36 s, 55°C 
for 45 s, 72°C for 1 min 20 s) and a final extension at 72°C for 10 min. The PCR 
product was first cleaved by 0.5 jul BamEI in IX K buffer, followed by 0.5 fil Sad 
in IX L buffer (all from Amersham Biosciences). Meanwhile, another fragment was 
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amplified from full-length Cs clone using primers 2536 and 1460-1441. PCR profile 
was the same as above except extending the elongation time to 2 min. It was then 
cleaved by BamYil in IX K buffer, followed by Kpnl in IX L buffer. Firstly, the 
Kpnl-BamRl and BamBl-Sacl fragments were ligated at 1:1 ratio (8.5 jul each) in a 
total volume of 20 fxl at room temperature for 1 to 2 hours. It was followed by an 
addition of 1.8 [jl\ of Kpnl-Sacl cut pUC18 vector and 0.2 /xl of T4 DNA ligase. The 
ligation product was incubated at 4°C overnight and transformed. The colonies were 
screened by PCR using primers 3026 and M13R，with the profile same as that 
described in session 2.3.3. PCR product of 1154 bp was resulted for clones bearing 
the insert. Plasmids were prepared as described in session 2.1.4 and subject to 
sequencing. Primers used in PCR amplification of HBV fragments, screening and 
sequencing were listed in Tables 2.6 and 2.7. 
2.4.4 Construction of a 1.3-fold HBV genotype Cs clone 
An HBV fragment (nt 2598-905) was generated by cleaving the full-length Cs 
clone with 0.5 \i\ each of Apal (New England Biolabs) and Kpnl in IX L buffer. 
Another fragment (nt 980-2598) was generated by cleaving first with Hindlll in 
OPA+，subsequently by Apal in IX L buffer. Similar to the method described in 
session 2.4.3, the two fragments were first ligated at room temperature, followed by 
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ligation to the vector. In this case, the HBV (nt 905-2000) clone cleaved with 0.5 jul 
each of Hindlll and Kpnl in IX L buffer acted as the vector. Colonies were screened 
by PCR using primers 903 and M13U, with the profile same as that described in 
session 2.3.3. PCR product of 1372 bp was resulted for clones bearing the insert. 
Plasmids were prepared as described in session 2.1.4 and subject to sequencing 
(Tables 2.6 and 2.7). 
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Table 2.8 Sets of primers used for PCR amplification of 2 HBV fragments 
in cloning HBV fragments (nt 980-2617) 
Fragment Name Sequence (5'to 3') Position Direction 
181 IF ACCATGCAACTTTTTCACC 1811-1847 sense Nil 
TCTGCCTAATCATCTCAT 
1 
SacI-2617R GCGAGCTCTTITCGTTAAC 2617-2589 antisense Sad 
TGTAAGAGGGCCCACATA 
HindIII-980F GCAAGCTTTGGAAAGTATG 980-1007 sense HindlU 
TCAAAGAATTGTGGGTCT 2 
1837R TAGGCAGAGGTGAAAAAG 1837-1801 antisense Nil 
TTGCATGGTGCTGGTGAAC 
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2.5 Cell Culture 
2.5.1 Cell culture maintenance 
Human hepatoma cells, Huh-7 from Japanese Collection of Research 
Bioresources Cellbank (JCBR), were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(FBS) (HyClone) and 1% streptomycin-penicillin (Invitrogen) at 37°C and 5% CO2. 
Huh-7 cells were also used in transfections of HBV genomes performed in VIDRL. 
Cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Thermo 
Electron Corporation) and 1% streptomycin-penicillin at 37°C and 5% CO2 The 
Huh-7 cells of VIDRL were slightly different from that of JCBR, as it had a much 
faster doubling time. 
2.5.2 Transient transfection of promoter clones 
Cells cultured in 75 cm^ culture flasks (Iwaki Glass Co., Ltd.) were trypsinized 
with 2 ml of trypsin-EDTA (Invitrogen) 1 day before transfection. Its concentration 
was then adjusted with complete DMEM for seeding. For performing dual-luciferase 
assay, 2.2 x 10^ Huh-7 cells were plated on 60-inm culture dishes (Iwaki Glass) in 5 
ml of DMEM. Growth media were changed before transfection. The ratio of 
FuGENE 6 transfection reagent (Roche Applied Science) to DNA used in 
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transfecting Huh-7 cells per 60-mm dish had been optimized as 8:5 by VIDRL. 
Therefore, 4 /xl of FuGENE 6 was added directly to 100 (xl serum-free DMEM and 
incubated for 5 min at room temperature. The diluted FuGENE 6 was then added to 
2.5 /xg of pGL3-promoter clone and 0.025 jxg of pRL-CMV plasmid. The FuGENE 
6:DNA complex was mixed and incubated for 20 min at room temperature. One 
hundred microlitres of complex was added to each 60-mm dish in a drop-wise 
manner. Dishes were swirled in crisscross to ensure even mixing. Transfections of 
each type of pGL3-promoter clones were performed in triplicate. Cells were 
incubated at 37�C and 5% CO2 for 2 days. 
2.5.3 Transient transfection of HB Vgenomes 
Cells were seeded at a split ratio of 1:10 on 60-mm dishes in 5 ml of DMEM 1 
day prior to transfection. Cells were approximately 60% confluent the next day. 
Before transfection, growth media were changed. Eight microlitres of FuGENE 6 
was added directly to 100 /xl serum-free OPTI-MEM (Invitrogen) and incubated for 
5 min at room temperature. The diluted FuGENE 6 was then added to 5 /xg of Sapl 
digested full-length HBV genome or 1.3-fold HBV clone, together with 0.1 /xg of 
pSEAP2-Control plasmid. After incubation at room temperature for 20 min, the 
complexes were added to the cells. Growth media were changed 2 days after 
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transfection. Intracellular cores were harvested 5 days after transfection. 
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Materials and Methods 
2.6 Dual-Luciferase® Reporter Assay System 
2.6.1 Principle of the assay 
A reporter gene system called Dual-Luciferase® Reporter Assay from Promega 
was used for this promoter study. In this system, firefly luciferase and Renilla 
luciferase are simultaneously expressed but individually measured. The promoter 
under investigation is cloned into a promoterless pGL3-basic vector (Fig. 2.2 A), 5' 
of the gene encoding the firefly luciferase. Thus, the activity of the promoter activity 
is reflected by the expression level of the firefly luciferase. The gene coding for 
Renilla luciferase is cloned under the control of a strong promoter in pRL-CMV (Fig. 
2.2 B). The Renilla luciferase is therefore highly and constitutively expressed in 
cells and serves as a transfection efficiency control in the experiment. The 
luminescent signal generated by the firefly luciferase reporter is first measured after 
adding Luciferase Assay Reagent II (LAR II). The signal is quenched and the 
Renilla luciferase signal is simultaneously initiated by adding Stop & Glo® Reagent 
to the same tube (Fig 2.3). 
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Fig. 2.2 Vector maps of pGL3-Basic and pRL-CMV. (A) pGL3-Basic is a 
promoterless vector. The promoter of interest is cloned into the multiple 
cloning site, upstream of/wc+. (B) pRL-CMV is co-transfected and serves as 
a transfection efficiency control. CMV immediate early enhancer/promoter is 
a strong promoter controlling the expression of Renilla luciferase. 
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Stop & Glo® 
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Fig. 2.3 Flow of Dual-Luciferase® Reporter Assay. Cell lysates are first 
added to LAR II. This reagent activates the firefly signal and reading from 
the first measurement activity of promoter of interest in pGL3-Basic. Stop & 
Glo® Reagent is immediately added to quench the firefly signal, and activate 
Renilla signal simultaneously. Reading from the second measurement reflect 
the transfection efficiency. 
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2.6.2 Cell harvest 
Cells were harvested 2 days after transfection. Followed by growth media 
aspiration and washing with 3 ml of phosphate buffered saline (PBS), cells were 
lysed with 400 jxl of IX Passive Lysis Buffer (Promega) for 15 min at room 
temperature. Cell lysates were centrifuged at 13,000 rpm for 30 s to remove cell 
debris and nuclei. 
2.6.3 Luciferase assay 
Assay was performed according to manufacturer's protocol. One hundred 
microlitres of LAR II (Promega) was pre-dispensed into each 12 x 75 mm PYREX® 
borosilicate glass tubes (Comings Incorporation). The single-tube luminometer, 
Lumat LB 9501, was programmed to a 5-second measurement period. Five 
microlitres of cell lysate was transferred into the glass tube and mixed by pipetting 2 
to 3 times. The tube was immediately placed in the luminometer for measurement of 
the luminescent signal from firefly luciferase reaction. Once the measurement was 
finished, 100 jitl of Stop & Glo® Reagent (Promega) was promptly added to the 
sample to quench the firefly luciferase luminescence and simultaneously activate the 
Renilla luciferase. The glass tube was put into the luminometer again for second 
measurement. 
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2.7 Data Analysis 
Transfection efficiency was normalized by calculating the ratio of firefly 
luciferase signal to Renilla luciferase signal. Results were expressed as fold increase 
relative to the promoterless pGL3-Basic plasmid. It was achieved by setting the ratio 
of pGL3-Basic plasmid as 1. Data were reported as means 士 standard deviations of 3 
independent experiments, with triplicate in each experiment. The means between the 
control and mutant clones were compared by applying the t test. A P value < 0.05 
was considered statistically significant. Analysis was performed using SPSS 11.5. 
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2.8 Extraction of HBV DNA from Intracellular Cores 
2.8.1 Harvest of intracellular cores 
Supernatant was collected for extracellular HBeAg and HBsAg. Cells were 
washed with 3 ml of PBS and then lysed with 800 /xl of lysis buffer (10 mM Tris pH 
7.5，1 mM EDTA, 50 mM NaCl and 0.5% NP-40) at 4°C for 15 min. Cell lysates 
were spun at 13,000 rpm for 5 min to remove the nuclei. Fifty microlitres of cell 
lysates were saved up for intracellular HBeAg and HBsAg assays. Then 2 /xl of 
DNasel (20U) (Roche Applied Science) and 8 of IM MgCh were added to each 
sample and incubated at 37°C for 1 hour. The intracellular cores were lysed by 
adding 200 jitl of 5X Stop buffer [2.5% (w/v) sodium dodecyl sulphate (SDS), 100 
mM Tris pH 7.5 and 125 mM EDTA] and 36 /xl of 15.6 mg/ml stock proteinase K 
(Roche Applied Science), which gave a final concentration of 0.5 mg/ml. The 
samples were incubated at 37°C overnight. 
2.8.2 Phenol/chloroform extraction 
Upon completion of proteinase K digestion, 800 jxl of phenol were added to each 
sample and mixed well. Phase separation was achieved by centrifugation at 13,000 
rpm for 7 min. Aqueous layer was attained and 800 of chloroform was added to it. 
Again, the samples were mixed and centrifuged at 13,000 rpm for 7 min to obtain 
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the aqueous layer. HBV DNAs were precipitated by adding 800 fxl of isopropanol 
and 2 /xl of glycogen (2 mg/ml), incubating at 4°C overnight. Samples were then 
centrifuged at 13,000 rpm for 10 min. Followed by removal of supernatant, pellets 
were washed with 150 fil of 70% ethanol. Centrifugation at 13,000 rpm for 5 min 
was performed to remove supernatant and pellets obtained were dried. Eventually, 
pellets were resupsended in 30 /il 5 mM EDTA and added in 2-3 jul lOX loading dye. 
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2.9 Southern Blotting 
2.9.1 Transfer of DNA to membrane 
Samples were run on a 1% agarose gel in IX TAE. Once completed, the gel was 
cut out and incubated in denaturation buffer (0.5 M NaOH, 1.5 M NaCl) for 20 min 
at room temperature on a rocking platform. It was then soaked in neutralization 
buffer [0.5 M Tris (pH 7.5), 1.5 M NaCl] and incubated for another 20 min at room 
temperature on a rocking platform. Gel was then ready for the transfer of DNA to a 
positively charged membrane. A piece of filter paper (Whatman 3MM) was placed at 
the bottom to act as a wick and draw transfer buffer, lOX SSC (1.5 M NaCl, 0.15 M 
sodium citrate), through the gel to the membrane. Then a positively charged 
Biodyne® nylon membrane (Pall Corporation), a piece of filter paper the same size 
as gel, and some paper towels were placed on top of the gel, as in written order. 
Transfer was performed overnight. Excess transfer salt solution was removed the 
next day by soaking the membrane in 2X SSC. DNA was cross-linked to membrane 
by baking the membrane at 120�C for 30 min 
2.9.2 Preparation of probes 
To prepare DNA for making probes, 1 /xg of HBV DNA (wild-type 1.5 times 
genome length, genotype A) was mixed with 1 /xl lOX Buffer B (Roche Applied 
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Science), 2 jul Eco¥N (20U) (Roche Applied Science) in a total reaction volume of 
10 jLtl. The mixture was incubated at 37°C for 1-1.5 hours. The digestion product 
was run on a 0.7% agarose gel. DNA fragment with size of 3.2 kb was cut and 
purified. Aliquots of 200 ng of DNA were prepared. Each aliquot was made up to a 
final volume of 10 jLtl with Tris-EDTA (TE) (10 mM Tris pH 7.5，1 mM EDTA). 
A 10 jul-aliquot of DNA template prepared above (An aliquot was enough for 
probing 4 blots) was boiled for 5 min and then quenched on ice for 5 min. Into the 
DNA template, 6 jLtl random primer extension reaction buffer (Perkin-Elmer), 6 jLtl 
dNTP (minus dCTP) (Perkin-Elmer), 2 fx\ Klenow enzyme (Roche Applied Science) 
and 7 fi\ of [of^^PJ-dCTP (Amersham Biosciences) were added and incubated at 37�C 
for 2 hr. Microspin sephadex G-50 column (Amersham Biosciences) was spun at 
5,000 g for 1 minute to settle the gel bed. After incubation, 20 pii of TE was added to 
probe bringing the volume up to 50 /xl. The probe was then added drop-wise to the 
top of the column and spun at 5,000 g for 2 min. The probe collected was added up 
to a volume of about 250 jul with TE. 
2.9.3) Hybridization with radiolabeled probes 
The membrane was incubated in a bottle containing 15 ml of prehybridization 
buffer [7% (w/v) SDS, 250 mM NaHzPCXt pH 7.0，1 mM EDTA] at 65°C for 2 hr. 
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Then the bottle was changed with fresh prehybridization buffer and 50 />tl of 
32p-HBV labeled probe was added. The DNA probe was denatured by boiling for 5 
min, followed by quenching on ice for 5 min before adding to the prehybridization 
buffer. For each blot, 50 fil of labeled probe was added and incubated overnight at 
42�C. Hybridization buffer was removed and the membrane was washed in wash 
buffer 1 (2X SSC, 0.1% SDS) for 10 min at 65°C. Afterwards, membrane was 
washed twice in wash buffer 2 (O.IX SSC, 0.1% SDS) for 30 min at 65 °C. 
Membrane was then placed in cassette with intensifying screens overnight and 
exposed to either phosphoimager screen or X-ray film. 
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2.10 Detection of HBsAg and HBeAg 
2.10.1 HBsAg assays 
In VIDRL, HBsAg was performed by an automated system. It was detected by 
IMx system (Abbott Laboratories), which was based on Microparticle Enzyme 
Immunoassay technology. One hundred and fifty microlitres of 4-fold diluted 
samples, either the culture media or the cleared cell lysates, were added to the 
reaction cell. It was followed by automatic addition of the IMx HBsAg reagents. 
In our own lab, HBsAg ELISA Kit (The Oriental Scientific Instruments 
Shanghai) was used. A 96-well microtitre plate with anti-HBsAg antibody 
immobilized onto the solid phase and all the reagents mentioned below were 
provided in the kit. To each well, 50 /xl each of positive control, negative control and 
samples were added. The plate was incubated with enzyme conjugate at 37°C for 1 
hour. The unbound molecules were removed by washing 5 times, each with 200 /xl 
of 20-fold diluted washing buffer. Finally, 50 /xl of Substrate A followed by 50 jLtl of 
Substrate B was added, and immediately incubated at 37°C for 7 min. The colour 
produced was measured by Microplate Reader 3550 (Bio-rad) at wavelength 450 nm. 
Duplicate was performed for each sample. 
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2.10.2 HBeAg assays 
Four-fold diluted samples, either the culture media or the cleared cell lysates, 
were delivered to Hepatitis Serology Laboratory in VIDRL for HBeAg Detection. It 
was performed by Murex HBeAg Kit (Abbott Laboratories), which was an assay 
based on enzyme linked immunosorbent assay technology. Results were measured at 
wavelength 450 nm. 
In our own lab, HBeAg ELISA Kit (The Oriental Scientific Instruments 
Shanghai) was used. Same procedures as HBsAg ELISA Kit were carried out. 
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2.11 SEAP Reporter Gene Assay 
The transfection efficiency of HBV genome experiments was controlled by the 
secreted alkaline phosphatase (SEAP) in the culture media. The SEAP Reporter 
Gene Assay (Roche Applied Science) was performed according to protocol and all 
the reagents mentioned below were provided in the kit. Briefly, 50 /xl of culture 
medium was diluted at a ratio of 1:4 with Dilution Buffer and incubated at 65�C for 
30 min. After centrifugation at 13,000 rpm for 30 s，50 fil of the heat-inactivated 
sample was transferred to each well of a microplate. It was followed by 5-minute 
incubation with 50 /xl of Inactivation Buffer at room temperature. Finally, 50 /jlI of 
Substrate Reagent was added and incubated at room temperature for 10 min while 
gently rocking. The light signal was detected by exposure to X-ray film for 5-10 s. 




CHAPTER 3 RESULTS 
3.1 Templates Selected 
All of the promoter locations in this study were determined according to 
locations previously determined by Renee McKay (School of Molecular and 
Biomedical Science, University of Adelaide, Australia) (Dewar, 2004). X pro/enhl is 
a region spanning nt 980-1373. In selecting templates for this region, the HBV 
isolates from patients' database were aligned with genotype B consensus sequence. 
An HBV isolate derived from chronic carrier 1 (CCl) was chosen because it shared 
99.8% identity with the X pro/enhl with the consensus sequence (Fig. 3.1). This 
template was used for generating a pair of control and mutant clones. Conversely, 
HBV isolate derived from HCC patient 1 (HI) (98.2% identity) was chosen and the 
hot spot mutation was mutated back to wild-type with an A to G change. Thereby, 
two pairs of clones were constructed so as to test whether the results correspond 
with each other. Likewise, the HBV genotype B isolates were aligned with the 
consensus in choosing template for pre-Sl promoter. It is a region from nt 
2706-2887. Isolates from chronic carrier 2 (CC2) and HCC patient 2 (H2) were 
chosen since they shared 100% identity with the pre-Sl promoter with the consensus 
sequence (Fig. 3.2). CC2 and H2 differed at nucleotide position 2712 (nt 2712), 
which was the site of the mutation. Therefore only one isolate was enough and CC2 
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was chosen. Mutant clones were constructed by changing the forward primer to one 
which harboured the mutation. When came to selecting template for core pro/enhll 
(nt 1575-1813), the sequences were aligned with genotype Cs consensus sequence. 
HBV isolates from chronic carrier 3 (CC3) and HCC patient 3 (H3) were chosen, 
both sharing 100% identity with the core pro/enhll regions (Fig. 3.3). The alignment 
of database with the respective consensus sequence was shown in the appendix. 
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989 999 1009 1019 1029 1039 
B GGAAAGTATG TCAACGAATT GTGGGTCTTT TGGGGTTTGC CGCCCCTTTC ACGCAATGTG 
CCl 
HI A 
1049 1059 1069 1079 1089 1099 
B GATATCCTGC TTTAATGCCT TTATATGCAT GTATACAAGC RAAACAGGCT TTTACTTTCT 
CCl A 
HI G A 
1109 1119 1129 1139 1149 1159 
B CGCCAACTTA CAAGGCCTTT CTRMGTAAMC AGTATCTGAA CCTTTACCCC GTTGCTCGGC 
CCl AA A 
HI C T AA A -
11=1169 1179 1189 1199 1209 1219 
BAACGG::TGG TCTGTGCCAA GTGTTTGCTG ACGCAACCCC CACTGGTTGG GGCTTGGCCA 
CCl 
HI £ 
1229 1239 丨 249 丨 259 1269 1279 
BTAGGCCATCA GCGCATGCGT GGAACCTTTG TGTCTCCTCT GCCGATCCAT ACTGCGGAAC 
CCl G 
HI 
1289 1299 1309 1319 1329 1339 
B TCCTAGCCGC TTGTTTTGCT CGCAGCAGGT CTGGRGCRAA ACTCATCGGG ACTGACAATT 
CCl G ~ A 
HI A — G — C 
1349 1359 1369 1373 
B CTGTCGTGCT CTCCCGCAAG TATACATCVT TTCC 
CCl A 
HI A - - C — 
Fig. 3.1 Alignment with genotype B consensus sequence in selecting 
template for X pro/enhl. X pro/enhl (nt 980-1373) is shown here. CCl 
and HI were sequences with greatest homology to the consensus when 
comparing X pro/enhl among 88 sequences. CCl was from chronic 
carrier 1 while HI was from HCC patient 1. Nucleotides bound by the 
red square (nt 1165) were the site of mutation studied. Mixed bases are 
represented by the lUPAC codes. R indicates A or G; M indicates A or 
C; V indicates A, C or G. 
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271^715 2725 2735 2745 2755 2765 
B CCAGAGSF \TG TAGTTAATCA TTACTTCCAG ACGMGACATT ATTTACACAC TCTTTGGAAG 
CC2 r c 
H2 C 
2775 2785 2795 2805 2815 2825 
B GCGGGKATCT TATATAAAAG AGAGTCCACA CGTAGCGCCT CATTTTGCGG GTCACCATAT 
CC2 G 
H2 G 
2835 2845 2855 2865 2875 2885 







Fig. 3.2 Alignment with genotype B consensus sequence in selecting 
template for pre-Sl promoter. The pre-Sl promoter region (nt 2706-2887) 
is shown here. CC2 and H2 were sequences with greatest homology to the 
consensus when comparing the pre-Sl promoter region among 88 
sequences. CC2 was from chronic carrier 2 while H2 was from HCC 
patient 2. Nucleotides bound by the red square (nt 2712) were the site of 
mutation studied. CC2 and H2 only differed by 1 nucleotide in the pre-Sl 
promoter region, which was nt 2712. Mixed bases are represented by the 




1584 1594 1604 1614 丨 624 1634 
Cs CCGTGTGCAC TTCGCTTCAC CTCTGCACGT CGCATGGJ^ CCACCGTGAA CGCCCGMCAG 
CC3 b C- - -
H3 C - - -
1694 
1644 丨 654 1664 1674 1684 
Cs GTCTTGCCYA AGGTCTTACA TAAGAGGACT CTTGGACTCT CAGCAATGTC AACGACCGAC 
CCS C 
H3 C 
1704 1714 1724 1734 1744 1754 
Cs CTTGAGGCAT ACTTCAAAGA CTGTGTATTT AARGACTGGG AGGAGTTGGG GGAGGAGAYT 
CCS A C-
H3 A T-
1764 1774 1784 1794 1804 1813 
Cs AGRTTAATGA TCTTTGTACT RGGAGGCTGT AGGCATAAAT TGGTCTGTTC ACCAGCACC 
CC3 —A G 
H3 — G A 
Fig. 3.3 Alignment with genotype Cs consensus sequence in selecting 
template for core pro/enhll. The core pro/enhll region (nt 1575-1813) is 
shown here. CCS and H3 were sequences with greatest homology to the 
consensus when comparing the core pro/enhll region among 84 sequences. 
CCS was from chronic carrier 3 while H3 was from HCC patient 3. 
Nucleotides bound by the red square (nt 1613) were the site of mutation 
studied. Mixed bases are represented by the lUPAC codes. R indicates A or 
G; M indicates A or C; Y indicates C or T. 
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3.2 Results of Luciferase Assays 
3.2.1 BCP mutation of genotype A as control 
The BCP mutation, A1762T and G1764A has been well-characterized and is 
known to reduce HBeAg expression (Buckwold et al., 1996; Hunt et al., 2000). It 
was used as control for the luciferase system and a decrease in promoter activity was 
expected. The wild-type promoter construct, pACore，and the mutant construct 
bearing the double mutations, pACoreM, were transiently transfected into Huh-7 
cells. The promoter activity pAoreC was 29.3-fold vs. pGL3-basic, while the mutant 
construct pACoreM was 18.1-fold vs. pGL3-Basic (P < 0.001). The promoter 
activity was decreased significantly by 38% (Fig. 3.4). Since a decrease in promoter 
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pGL3-Basic pACore pACoreM 
Fig. 3.4 Effect of BCP mutation on core pro/enhll activity. This double 
mutation, A1762G and T1764A, markedly reduced the core pro/enhll promoter 
activity in Huh-7 cells. The pRL-CMV vector was cotransfected to normalize 
varying transfection efficiencies. The relative promoter activity of each 
construct is shown as the fold increase over a promoterless luciferase control 
pGL3-Basic, whose activity is determined as 1，after being normalized to 
Renilla luciferase activity. Values shown in figures represent means 士 SDs of 
three individual experiments in triplication. • , P < 0.001 vs pACore construct. 
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3.2.2 Effect of CI 165 T mutation on X pro/enhl activity of HBV genotype B 
The promoter activity of X pro/enhl was strong with several-hundred-fold 
greater than promoterless pGL3-Basic vector. Fig. 3.5 shows the results of 
promoters derived from chronic carrier. Promoter activity of pXC was 279-fold vs. 
pGL3-basic, while the mutant construct pXC/1165T was 286-fold vs. pGL3-Basic (P 
> 0.1). Similar results of promoters derived from HCC patient were observed (Fig. 
3.6). Promoter activity of pXH was 310-fold vs. pGL3-basic, while the mutant 
construct pXH/1165C was 291-fold V5. pGL3-Basic (P > 0.1). The point mutation at 
1165 did not affect the promoter activity. 
3.2.3 Effect of T2712C mutation on pre-Sl promoter activity of HB V Genotype B 
The promoter construct pPreSl and the mutant construct pPreSl/2712C were 
transiently transfected into Huh-7 cells. Cells were lysed 2 days after transfection 
and luciferase assay was performed. The pre-Sl promoter activity was weak with 
only 8- to 9-fold greater than background (Fig. 3.7). Promoter activity of pPreSl 
was 8.5-fold V5. pGL3-basic, while the mutant construct pPreSl/2712C was 9.0-fold 
vs. pGL3-Basic {P > 0.1). The point mutation did not affect the promoter activity. 
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pGL3-Basic pXC pXC/1165T 
Fig. 3.5 Effect of C1165T mutation on X pro/enhl activity demonstrated by 
constructs derived from HBV chronic carrier (CI). It did not alter the X 
pro/enhl promoter activity in Huh-7 cells. The pRL-CMV vector was 
cotransfected to normalize varying transfection efficiencies. The relative 
promoter activity of each construct is shown as fold increase over a 
promoterless luciferase control pGL3-Basic, whose activity is determined as 1， 
after being normalized to Renilla luciferase activity. Values shown in figures 
represent means 士 SDs of three individual experiments in triplication. 
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pGL3-Basic pXH pXhV1165C 
Fig. 3.6 Effect of T1165C mutation on X pro/enhl activity demonstrated 
by constructs derived from HCC patient (HI). Same as the result in Fig. 
3.5, no change in promoter activity was observed. The pRL-CMV vector 
was cotransfected to normalize varying transfection efficiencies. The 
� relative promoter activity of each construct is shown as fold increase over a 
promoterless luciferase control pGL3-Basic, whose activity is determined 
as 1，after being normalized to Renilla luciferase activity. Values shown in 
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pGL3-Basic pPreSI pPreS1/2712C 
Fig. 3.7 Effect of T2712C on pre-Sl promoter activity. It did not 
change the pre-Sl promoter activity in Huh-7 cells. The pRL-CMV 
vector was cotransfected to normalize varying transfection efficiencies. 
The relative promoter activity of each construct is shown as the fold 
‘ increase over a promoterless luciferase control pGL3-Basic, whose 
activity is determined as 1，after being normalized to Renilla luciferase 
activity. Values shown in figures represent means 士 SDs of three 
individual experiments in triplication. 
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3.2.4 Effect of G1613A mutation on core pro/enhll activity of HB V Genotype Cs 
The promoter activity of core pro/enhll from the naturally occurring HBV 
isolates, i.e. CC3 and H3, were around 20-fold greater than pGL3-basic. Fig. 3.8 
shows that mutation at 1613 from G to A resulted in a significant increase in 
promoter activity. Promoter activity of pCoreC was 21.8-fold V5. pGL3-basic, while 
the mutant construct pCoreC/1613A was 34.5-fold V5. pGL3-Basic (P < 0.001). The 
promoter activity was increased drastically by 58% as a result from this mutation. 
The effect also holds true in the case of HCC constructs. Mutation at 1613 from A to 
G resulted in a significant decrease in promoter activity. Promoter activity of 
pCoreH was 28.2-fold vs. pGL3-basic, while the mutant construct pCoreH/1613G 
was 14.7-fold v .^ pGL3-Basic {P < 0.005). The promoter activity was decreased by 
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pGL3-Basic pCoreC pCoreC/1613A 
Fig. 3.8 Effect of G1613A mutation on core pro/enhll activity 
demonstrated by constructs derived from HBV chronic carrier (C3). It 
markedly increased the core pro/enhll activity in Huh-7 cells. The 
pRL-CMV vector was cotransfected to normalize varying transfection 
efficiencies. The relative promoter activity of each construct is shown as 
the fold increase over a promoterless luciferase control pGL3-Basic, whose 
activity is determined as 1，after being normalized to Renilla luciferase 
activity. Values shown in figures represent means 士 SDs of four individual 
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pGL3-Basic pCoreH pCoreH/1613G 
Fig. 3.9 Effect of A1613G mutation on core pro/enhll activity 
demonstrated by constructs derived from HCC patient (H3). It markedly 
decreased the core pro/enhll activity in Huh-7 cells. The pRL-CMV vector 
was cotransfected to normalize varying transfection efficiencies. The relative 
�� 
promoter activity of each construct is shown as the fold increase over a 
promoterless luciferase control pGL3-Basic, whose activity is determined as 
1，after being normalized to Renilla luciferase activity. Values shown in 
figures represent means 士 SDs of four individual experiments in triplication. 
* ,P< 0.005 V5 pCoreH construct. 
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3.2.5 G1613A and BCP mutation 
BCP mutation is reported to be strongly associated with HBV genotype C (Orito 
et al., 2001; Chan et al., 2002). Our database concurred with this observation. 
Among all genotype Cs isolates derived from chronic carriers, 28 out of 37 (75.7 %) 
harboured the BCP mutation. The double mutations have been reported to increase 
risks of HCC (Fang et al., 2002; Kao et al., 2003). Similarly, G1613A was found to 
be a marker for HCC development in the case-control study conducted earlier. Yet, 
their effects on promoter activity of core pro/enhll are in opposite. BCP mutation 
reduces the promoter activity while mutation at nt 1613 was found to increase the 
activity in our study. Therefore it is interesting to test on the combined effect of the 
mutations. Fig. 3.10 shows the sites of mutations on the 4 constructs. HBV sequence 
in pCoreC construct was naturally occurring while the rest of them were synthetic. 
An increase in promoter activity was observed when the BCP mutation on pCoreC 
were mutated back from T/A to wild-type nucleotides A/G at 1762/1764. Promoter 
activity of pBCPwt was 26.1-fold V5. pGL3-basic, while pCoreC was 21.8-fold vs. 
pGL3-Basic (Fig. 3.11). A slight (16.5 %) but statistically significant decrease {P < 
0.001) was detected with the BCP mutation in HBV genotype Cs. Promoter activity 
of pCoreC/1613A was even higher than pBCPwt, with 33.8-fold V5. pGL3-Basic. 
Among all of them, pl613A-BCPwt was the highest, with 41.9-fold V5. pGL3-basic. 
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1613 1762 1764 
I I I 
pCoreC/1613A CGCATGGAAA AGRTTAATGATCTTT 
pBCPwt-1613A CGCATGGAAA AGRTTAAAGGTCTTT 
pCoreC CGCATGGAGA AGRTTAATGATCTTT 
pBCPwt CGCATGGAGA AGRTTAAAGGTCTTT 
Fig. 3.10 The combinations of mutation at 1613 and BCP mutation of 
the 4 constructs. Nucleotides at 1613, 1762 are 1764 are shown in red. 
� 1613G and 1762A/1764G are wild-type nucleotides. HBV sequence of 
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pGL3-Basic pBCPwt pCoreC p1613A- pCoreC/1613A 
BCPwt 
Fig. 3.11 Interaction between G1613A and BCP mutation in Huh-7 cell. 
The pRL-CMV vector was cotransfected to normalize varying transfection 
efficiencies. The relative promoter activity of each construct is shown as 
the fold increase over a promoterless luciferase control pGL3-Basic, whose 
activity is determined as 1，after being normalized to Renilla luciferase 
activity. Values shown in figures represent means 士 SDs of three individual 
experiments in triplication. *,P< 0.001 vs pBCPwt construct. 
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3.3 Full-length HBV Genome Clones 
3.3.1 Construction of replication-competent full-length HBV genome clones 
Given that genotype C is prevalent in Asia, construction of infectious genotypes 
Cs and Ce clones was indispensable for further HBV research. An infectious 
genotype Cs clone is especially desired as it is useful in downstream investigation of 
mutant G1613A. Ce and Cs HBV sequences derived from chronic carriers without 
HCC were cloned. Cs was found to be infectious as shown by the presence of 
replicative intermediates. Though the signal was weak compared to wild-type, 
double-stranded genome, single-stranded genome and smear were detected in 
Southern blot assay (Fig. 3.12). It was consistent with the results of HBeAg and 
HBsAg assays (Tables 3.1 and 3.2). HBsAg was secreted to culture media as 
reflected by a high S/N ratio. Intracellular and extracellular HBeAg were also 
detected positive as the ratios of OD450 to cut-off value were greater than 1. On the 
contrary, no band of Ce clone was observed after Southern blot assay. This might 
probably due to failure in transfection as shown by the SEAP assay (Fig. 3.13). No 
HBeAg and HBsAg were detected in the culture media. Interestingly, even no 
replication was detected for Ce clone in the first experiment, intracellular HBeAg 
and HBsAg were both detected positive, indicating expression of both antigens 
inside the cells. The experiment was repeated a second time and disappointedly, both 
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Ce and Cs clones failed to generate any replicative intermediates (Fig. 3.14). Results 
of Cs clone correlated with the negative results in SEAP assay (Fig. 3.15), detection 
of extracellular HBeAg and HBsAg (Tables 3.3 and 3.4). However, Ce was 
successfully transfected in the repeat experiment and yet failed to generate 
replicative intermediates and to secret HBeAg and HBsAg into culture media. This 
suggested that Ce construct was defective in replication. 
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Ce Cs wt 
mm 
! l 
Fig. 3.12 Detection of replicative intermediates by Southern blot 
after first transfection of constructs into Huh-7 cells. Both wt and Cs 
constructs were infectious, as HBV replicative intermediates were 
detected. However, no signal was detected for Ce construct, ds, 
double-stranded viral genome; ss, single-stranded viral genome; wt, 
wild-type 
Ce Cs wt 
Fig. 3.13 Transfection efficiency monitored by SEAR The 
transfection of Ce failed, wt, wild-type. 
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Table 3.1 Detection of intracellular and extracellular HBsAg in first 
transfection experiment 
Sample S/N" Interpretation 
Negative Control^ 1.30 -
Positive Control' 58.62 + 
Ce 106.50 + 
Intracellular . Cs 161.44 + HBsAg wild-type 286.29 + 
^ Ce 4.08 +/-Extracellular Cs 104.60 + HBsAg 
wild-type 116.72 + 
“S/N is defined as mean sample to negative 
b Negative control has a range of 0.75 - 1.30 in S/N ratio 
Positive control has a range of 7.00 - 63.00 in S/N ratio 
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Table 3.2 Detection of intracellular and extracellular HBeAg in first 
transfection experiment 
Sample OD450 OD/CO"’" Interpretation 
Negative Control 0.051 0.34 -
Positive Control 0.747 ^ + 
Ce 0.15 0.99 +/-Intracellular 
… . Cs 1.879 12.4 + HBeAg wild-type OWR^ > 19.9 + 
Ce 0.048 0.32 一 Extracellular Cs 2.402 15.9 + HBeAg wild-type 0.751 ^ + 
“Cut-off value (CO) is equal to reading of negative control + 0.1，i.e. 0.151 
b OD/CO^ 1 is positive 
c OWR means out of reader working range (> 3 OD) 
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d s _ M 
w 
Fig. 3.14 Detection of replicative intermediates by Southern 
blot after second transfection of constructs into Huh-7 cells. 
Both Ce and Cs constructs failed to replicate, ds, 
double-stranded viral genome; ss, single-stranded viral 
genome; wt, wild-type 
Ce Cs wt 
• 參 
• 參 
Fig. 3.15 Transfection efficiency monitored by SEAP. Cs 




Table 3.3 Detection of intracellular and extracellular HBsAg in second 
transfection experiment 
Sample Rate “ Interpretation 
Negative Control 6.4 -
Positive Control 269.9 + 
T „ , Ce 608.0 + Intracellular A Cs 650.4 + HBsAg wild-type 1311.5 + 
^ Ce 130.2 -Extracellular Cs 17.2 -HBsAg 
wild-type 756.4 + 
“ Unfortunately, some errors occurred in the system and therefore S/N 
was not calculated in this particular experiment. Rate was therefore 
shown here instead of S/N, which was the raw data. 
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Table 3.4 Detection of intracellular and extracellular HBeAg in second 
transfection experiment 
Sample OD450 OD/CO"力 Interpretation 
Negative Control 0.051 0.34 -
Positive Control 0.747 4.95 + 
Ce 0.204 1.35 + • 
Intracellular t td a CS 0.208 1.38 + HBeAg wild-type OWR" >19.9 + 
Ce 0.05 0.33 -Extracellular Cs 0.054 0.36 -HBeAg wild-type 0.591 m + 
“ C O is equal to reading of negative control + 0.1，i.e. 0.151 
b OD/COg l i s positive 




3.3.2 Drawbacks of the system 
As introduced previously, the full-length HBV genome can be excised from the 
recombinant plasmid by Sapl and recircularized once it is transfected into the cells. 
This system prevails over tandemly arranged HBV dimer or terminally redundant 
HBV genomes in a way that it contains only 1 copy of each ORF, therefore mimics 
more closely to the transcriptional template during natural HBV infection (Lai and 
Locamini, 2002). Nonetheless, the use of a monomeric HBV genome in transfection 
was much more difficult than expected. Sapl, which played a crucial role in 
generating the monomeric HBV genome before transfection, was found to be 
inefficient in restriction cut. Incomplete digestion was observed most of the time as 
shown in Fig. 3.16. Problem was aggravated by the appearance of DNA fragments 
with incorrect size (usually larger in size) in several occasions (Fig. 3.16). Different 
conditions were set up in attempt to troubleshoot the problem (Table 3.5). Same set 
V of conditions were applied to another tube of Sapl, which was proven to work well 
before, and all the digestion reactions resulted in DNA fragments with correct size. 
In contrast, the problematic Sapl failed in all conditions (Fig. 3.17). The reason of 
the problem was unclear and it was likely to be problem related to individual tube of 
enzyme. Even when DNA fragments with correct size were obtained, another 
technical problem arose. Gel extraction was performed to retrieve full-length HBV 
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genome and it resulted in great loss of DNA fragment. Since 5 fig of HBV DNA was 
needed for each transfection, a tremendous amount of recombinant plasmids had to 
be digested before transfection. Furthermore, the transfection of Cs construct was 
successful only for the first experiment but failed in the second one as shown in Figs. 
3.12 and 3.14 respectively. The transfection of the monomeric HBV construct was 
less reliable than the 1.5-fold wild-type HBV genotype A construct. This construct 
was kindly provided by VIDRL as a positive control. It started from the X pro/enhl 
and extended more than one genome length to include duplicate copies of X ORF 
and polyadenylation (poly A) signal located downstream of core pro/enhancer II. In 
this case, all of the ORFs were uninterrupted so that the construct could be 
transfected as a whole plasmid without any modification before hand. In view of the 
fact that greater than full-length genome construct was easier to handle technically, 
the Cs construct was therefore subsequently reconstructed. 
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A M B 
undigested plasmid 
HBV—— plasmid— 
Fig. 3.16 Digestion of Cs done by Sapl. Correct sizes of fragments 
were obtained after digestion in lane A. However, Sapl was weak and 
� resulted in incomplete digestion. Cs clone was digested by a new tube 
of Sapl in lane B. In this case, fragments cut were with incorrect sizes. 
Digestion conditions were then changed several times, but failed to 




Table 3.5 Different setups of Sapl digestion 
No. Samples Total volume (|xl) 
1 pUC19(own lab) 
2 pUC19 (borrowed) 
3 Cs clone _ 20 
4 Ce clone 
5 Cs clone (Dried, re-eluted with water)" 
6 Cs clone (Dried, re-eluted with water)“ 
7 Cs clone 10 
a In order to remove any residual ethanol after gel extraction, if there was 
any. 
In each of the setups, 2U/^g Sap\ was used to digest l^ig of DNA. All of 
them were incubated at 37°C for 16 hr. 
A B I ‘ 1 I ‘ 1 
1 2 3 4 5 6 7 M 1 2 3 4 5 6 7 
• • 
Fig. 3.17 Digestion with different conditions in attempt to 
troubleshoot the problem. Digestions in batch A was performed by a 
Sapl proven to work well before, and acted as the positive control. 
While batch B was performed by the problematic Sapl enzyme. 
Numbers 1-7 correspond with the conditions listed in Table 3.5. Lane 
M was 1 kb DNA ladder GeneRuler®. 
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3.4 Construction of a Replicative-competent 1.3-fold HBV 
Clone 
3.4.1 Construction of the HBV (nt 979-2617) clone 
The 1.3-fold HBV infectious clone was designed to follow the organization of 
the 1.5-fold HBV clone from VIDRL (Fig. 3.18A), only with a shorter genome 
length. It started from the X pro/enhl and extended more than one genome length to 
include two copies of X ORF (Fig. 3.18B). It ended 80 bp downstream of the poly A 
signal to include the c/5-regulatory elements' for effective replication. As the Cs 
construct started at nucleotide 1821 and ended at nucleotide 1825, extensions were 
needed at both ends of the HBV genome (Fig. 3.18B). A partial HBV DNA fragment 
was therefore cloned to serve as template for generating the 2 fragments that joined 
at the 5’ and 3’ ends of HBV genome. The fragment was from nt 979-2617. Cloning 
of this fragment was summarized in Fig. 3.19. Briefly，two fragments were amplified 
using the Cs construct as template. One was from nt 979-1837 while the other one 
was from nt 1811-2617. These 2 fragments overlapped each other from nt 
« 
1811-1837 (27 bp) and were joined together by PCR. Eventually, a fragment with 
size of 1639 bp was generated (Figs. 3.20 and 3.21). It was cloned into vector 




1.5-fold HBV genotype A genome 
^ ^ ^ ^ poly A 
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C \ |preC| C ^ Polymerase 
Key 
X pro/enhl (from nucleotide 980) 
BCP 
B 
980 1821 1825 2000 
• 3215/1 • 
I 1 I Full-length Cs HBV genome 
1 8 2 1 1 8 2 5 
^ ^ ^ ^ poly A 
X I [ ^ [ s ^ l S I " X signal 
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Polymerase 
Fig. 3.18 Schematic diagrams illustrating the genomic organization of the 
constructs. (A) A 1.5-fold wild-type genotype A construct from VIDRL. 
(B) A schematic diagram illustrating the genomic organization of 1.3-fold 
Cs construct which was to be reconstructed. The ftxll-length Cs construct 
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1 ‘ ~ 2.0 16 kb -1.5 kb 
Fig. 3.20 The two fragments were joined together by PCR to 
give a fragment of 1.6 kb. Lane M was 1 kb DNA ladder. 
Clones 1 to 8 (left to right) 
I 1 M 
• — — 2 . 0 kb — 1 . 5 kb 
Fig. 3.21 Colony PCR to check the presence of insert. Clones 
2, 3，4 and 8 were clones bearing the HBV fragment. Lane M 
was 1 kb DNA ladder 
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3.4.2 Construction of the HB V (nt 905-2000) clone 
The re-construction of the Cs clone into a 1.3-fold infectious clone was basically 
divided into 2 parts. First part was the extension from nt 1825-2000. An HBV 
fragment from nt 1186-2000 was amplified using HBV (nt 979-2617) construct as 
template. This fragment harboured an internal BamRl restriction site and an 
artificially introduced Sad site. Cs was an early work and cloned into vector pUC19. 
It became incompetent with the cloning system developed later on, which was 
changed to vector pUC18. Therefore BamRl-Sacl fragment could not simply 
exchange with that of the Cs construct. Instead, it was first ligated with Kpnl-BamHl 
fragment (nt 905-1825) from Cs construct. Successful ligation was confirmed as a 
very faint band with size of about 1.1 kb was observed on an agarose gel (Fig. 3.23). 
It was then followed by ligation with pUC18. Colony PCR was performed to check 
for presence of insert. A band of around 820 bp was observed for clones containing 
the insert (Fig. 3.24). The recombinant plasmid constructed was served as vector for 
the second part of cloning. The flow of cloning HBV fragment (nt 905-2000) is 
summarized in Fig. 3.22. 
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LI kb fragment 
^ Fragment excess 
Fig. 3.23 Ligation of two fragments were checked by gel 
electrophoresis before ligating with the vector. It was successful 
as a faint band of 1.1 kb was observed. Lane M was 1 kb DNA 
ladder whereas lane L was the ligation product. 
Clones 1-10 (left to right) 
厂 I I -ve M 
I H 
Fig. 3.24 Colony PCR to check the presence of insert. 




3.4.3 Construction of 1.3-fold genotype Cs HB V clone 
Second part was the insertion of fragment nt 979-1821 at 5’ end. It is 
summarized in Fig. 3.25. A Hindlll-Apal fragment was obtained by digestion of 
HBV (nt 979-2617) construct. It was then ligated with Apal-Kpnl fragment from Cs 
construct. Again, successful ligation was confirmed by running on an agarose gel. A 
faint band with size of about 3.1 kb was observed in Fig. 3.26. The recombinant 
plasmid generated in first part was digested with HindRl and Kpnl and served as 
vector. It was ligated with the 3.1 kb fragment to give a 1.3-fold HBV construct. 
When checking the presence of insert by colony PCR, a vector primer and a primer 
flanking region after nucleotide 2000 was chosen, so as to avoid any ambiguity 
caused by the redundant HBV genome. A band of around 1.4 kb was observed for 
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Fig. 3.25 The flow of constructing 1.3-fold Cs construct. It was 
achieved by inserting an HBV fragment, which was from nt 
979-2598，into HBV (nt 905-2000) clone. 
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L M Jm 3.1 kb fragment n P ^ ^ ^ ^ H 1 
Fig. 3.26 Ligation of two fragments were checked by gel 
electrophoresis before ligating with the vector, HBV (nt 905-2000) 
clone. It was successful as a faint band of 3.1 kb was observed. Lane 
M was 1 kb DNA ladder whereas lane L was the ligation product. 
Clones 1 to 10 (left to right) 
Fig. 3.27 Colony PCR to check the presence of insert. Clones 1 to 7 
harboured the inserts. Lane DC was colony grew on plate that was 
spread with transformants of double-digested vector, acting as a 
negative control. Lane M was the Ikb DNA ladder. +，PCR positive 
control with HBV plasmid as template; -，PCR negative control 
without any template. 
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3.4.4 Test for replication competency 
The 1.3-fold HBV genotype Cs clone obtained had to be tested on its replication 
competency. The constructs were transfected into Huh-7 cells and harvested 5 days 
after transfection. HBeAg and HBsAg in the culture media were detected by ELISA 
and both gave positive results. These were characteristics of an infectious HBV 
clone. However, it was not enough to prove it replicative. The critical assay was 
Southern blot hybridization, which showed clearly the presence of replicative 
intermediates or not. The HBV DNA was extracted from intracellular cores and 
ready for analysis. However, at the time of writing this thesis, the Southern blot 
assay was still in optimization in our lab based on the protocol provided by VIDRL. 
Therefore, the HBV DNA would be analyzed in future. 
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Table 3.6 Extracellular HBsAg secreted by cells transfected with 
1.3-fold Cs construct 
Sample OD450 Interpretation 
Positive Control 2.466 + 
Negative Control -0.074 -
a 2.729 + 
a According to the kit, if negative control < 0.05, considered it as 0.05 in 
calculation of CO. In this case, CO is equal to negative control x 2.1, 
i.e. 0.105. 
b OD450 ^  CO is positive. 
Table 3.7 Extracellular HBeAg secreted by cells transfected with 
1.3-fold Cs construct 
Sample OD450 Interpretation^ 
Positive Control 2.025 + 
Negative Control 0.0105" -
Cs 2.065 + 
“ According to the kit, if negative control < 0.05, considered it as 0.05 in 
calculation of CO. In this case, CO is equal to negative control x 2.1, i.e. 
0.105. 
b OD450 ^  CO is positive. 
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CHAPTER 4 DISCUSSION 
4.1 BCP Mutation as Control of the Luciferase Assay 
A double mutation at BCP is frequently found in patients with symptoms of 
chronic hepatitis, resulting in approximately 70% of decrease in HBeAg expression 
but modestly increase the viral replication rate (Buckwold et al., 1996; Tang et al.’ 
2001; Locamini et al., 2003). The reduction of HBeAg expression was apparently 
mediated by the suppressed precore mRNA transcription. A recent study (Zheng et 
al., 2004) has shown that a liver-enriched transcription factor HNFl suppressed the 
precore mRNA expression. Since the double mutation creates a new HNFl binding 
site, this result explained why a decrease in precore mRNA synthesis is observed 
when the mutation occurs, (Li et al, 1999; Tang et al., 2001). On the other hand, the 
mechanism of enhanced viral replication is more complicated, involving mutation in 
overlapping X ORF, differential effect of transcription factors such as HNF4 and 
RXRa-PPARa on replication, and changes in the ratio of precore mRNA to pgRNA 
(Tang et al., 2001; Laras et al, 2002; Parekh et al” 2003). Since the effect of BCP 
mutation has been extensively characterized, a pair of wild-type and BCP mutant 
clones were used as the control of our luciferase assay. The promoter activity of the 
mutant was found to decrease by 38% when comparing with the wild-type. This 
result was in agreement with previous studies, which have reported the reduction of 
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HBeAg expression. Furthermore, the decrease was significant and could be detected 
by the luciferase assay. In this regard, the system was validated and used in the study 




4.2 Promoter Activities Not Altered by T2712C and C1165T 
Among 3 of the markers identified in HBV Genotype B, 2 of them were located 
in the promoter. One was at T2712C in pre-Sl promoter whereas the other one was 
C1165T in X pro/enhl. Results revealed that both mutations did not confer any 
change on the promoter activity. Despite of that, the potential effect of mutation on 
another ORF could not be overlooked, given that the four ORFs in HBV genome are 
partially overlapping. The nucleotide 2712 is not only located at pre-Sl promoter, 
but is also located at the P ORF. The mutation leads to an amino acid change from 
tyrosine to histidine at residue 136，which is located at the terminal protein (TP) 
domain of the polymerase (tpY136T). The TP domain involves in the priming step 
during the initiation of minus-strand DNA synthesis from pgRNA (Lai and 
Locamini, 2002). It was achieved by formation of a phosphodiester bond between 
the tyrosine residue 63 and the first nucleotide of minus-strand DNA (Lanford et al., 
1997). Further study is required to find out if mutation tpY136T could have any 
effect on the priming step, hence the replication capacity. For nucleotide 1165，it is 
located at the RNaseH domain of polymerase gene, in addition to X pro/enhl. It 
leads to an amino acid change from serine to proline at residue 2 of the polymerase. 
This domain is responsible for the degradation of RNA template after the 
minus-strand DNA synthesis (Lai and Locamini, 2002). This step is not as critical as 
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the priming step and the reverse transcription in the replication cycle. In this regard, 
this mutation is less likely to have any significant effect on replication. Until now, 
hardly any mutation on RNaseH domain with significant effect on replication or 
clinical implication has been reported. 
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4.3 Mutation G1613A of Core pro/enhll 
4.3.1 Mutation resides in negative regulatory element of core promoter 
Our results indicate that the point mutation G1613A increases core pro/enhll 
activity and vice versa. From the results of 2 sets of experiments, the change in 
promoter activity conferred by this point mutation is around 50%. This change is 
drastic and comparable with the results of BCP mutation, which reduces the 
promoter activity by 38%. Core pro/enhll, as mentioned earlier, includes both the 
core promoter and enhancer II，which are overlapping with each other. The core 
promoter can be divided into BCP and the core upstream regulatory sequence 
(CURS) (Kramvis and Kew, 1999). CURS is a cw-acting element immediately 5' of 
BCP and is known to activate BCP in well-differentiated liver cells by 
200-2000-fold, in orientation- and position-dependent manners (Yuh et al.’ 1992; 
Guo et al” 1993). Its stimulatory effect can be partially abolished by a regulatory 
sequence further upstream, known as negative regulatory element (NRE). Mutation 
G1613A is located at this region (Fig. 4.2). 
4.3.2 NRE and NRE-binding protein 
The NRE can repress the activity of CURS region of core promoter and 
enhancer II by 10-20 fold (Lo and Ting, 1994; Chen and Ou, 1995). Sun et al has 
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previously cloned and characterized an NRE-binding protein, which was named as 
NREBP (Sun et al., 2001). NREBP cDNA is 8266 nucleotides in size and encodes a 
protein of 2386 amino acids. Expression of NREBP transcripts can be detected in all 
tissues, though weaker in liver. In the study, formation of DNA-protein complex 
between NRE and the nuclear proteins was abrogated by an antibody against 
NREBP. It suggests that NREBP is the endogenous NRE binding protein present in 
cells. Overexpression of N-tmncated NREBP can further enhance the repressive 
effect mediated by NRE, as well as reducing production of HBV transcripts and 
virions. It was reported that the consensus sequence for NREBP binding is 
GA(G/T)AN(C/G)(AyG)CC. This motif matches perfectly with the NRE sequence in 
the HBV genome (GAGACCACC). The nucleotide underlined in the binding 
sequence is equivalent to nucleotide 1613 in our study. It is conceivable that a 
nucleotide exchange from G to A may hamper the binding of NREBP to NRE, hence 
the repressive effect on CURS and enhancer II can be rescued, leading to an increase 
in the core pro/enhll activity. Previous studies have revealed that NREBP can bind 
specifically with the wild type NRE sequence, but not with mutants (Lo and Ting, 
1994; Sun et al., 2001). Those mutants tested were either random mutant or 
sequences bearing mutations from nucleotide 1614. Mutation on nucleotide 1613 
has not been tested before. Further experiments are needed to test our hypothesis. 
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< Core promoter • 
1613 1636 1742 1849 
NRE CURS BCP 
1627 Enhancer II 1774 
Adapted from Moolla et al., 2002 
Fig. 4.1 The organization of core pro/enh II. A schematic diagram 
showing the structural domains of BCP, the upstream regulatory elements 
(NRE and CURS) and enhancer II. The nucleotide positions with respect to 
the EcoBl site are indicated by the numbers on top. 
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4.3.3 Relationship with BCP mutation 
The effects of mutations at nucleotide 1613 and BCP are antagonistic. When 
comparing pCoreC with pBCPwt, the decrease in promoter activity attributed by 
BCP mutation is retained in HBV genotype Cs. Surprisingly, this decrease (16.5%) 
is smaller than what we had obtained earlier using clones of genotype A. Similar 
results were obtained when comparing pCoreC/1613A with pl613A-BCPwt. Slight 
decrease in promoter activity was detected and it was found to be statistically 
insignificant (p = 0.08). Whether this observation is sample specific or genotype 
specific is unclear and awaits further study. The promoter activity of pCoreC/1613A 
is higher than pBCPwt, showing that the effect of G1613A counteracts and even 
overrides the effect of BCP mutation. Same conclusion could be drawn when 
comparing pBCPwt, pl613A-BCPwt and pCoreC/1613A. Interestingly, HBV 
variant with BCP mutation has been proposed to have survival advantage because it 
reduces the expression of HBeAg. It has been suggested that HBeAg serves as a 
decoy to buffer anti-core protein immune response. However, the anti-HBe immune 
response can effectively reduce the viral load. Under this strong selection pressure, 
viral variants with less or none HBeAg expression are thereby favoured (Locamini 
et al., 2003; Parekh et al., 2003; Tacke et al., 2004). Moreover, several reports have 
suggested an association between BCP mutation and HCC (Baptista et al” 1999; 
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Fang et al., 2002; Kao et al” 2003). In contrast, mutation G1613A, which is also 
identified as a marker for HCC, conferred contradictory effect in the reporter gene 
assay. Thus, it is interested to determine if this point mutation will result in an 
increase in precore mRNA transcription and HBeAg expression. If this hypothesis is 
true, it will violate the above assumption on selective advantage for HBV variants 
with less or none HBeAg expression. Also, the impact on replication efficiency has 
to be investigated. Furthermore, the effects of mutation G1613A in combination with 
BCP mutation on HBeAg expression and replication efficiency have to be studied. 
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4.4 HBV Constructs 
4.4.1 Rationale in re-construction of 1.3-fold HB V clone 
A replication-competent HBV genotype Cs clone is required for functional 
analysis of mutation G1613A. Initially, the approach proposed by Gunther et al. 
(Gunther et al., 1995) was pursued. The monomeric HBV is excised from the 
plasmid with the application of Sapl prior transfection. Sapl was however found to 
be an inefficient enzyme, time-consuming digestion was required before each 
transfection. Moreover, this method depends on the re-circularization of monomeric 
HBV inside the cells. Therefore, re-construction of the HBV DNA clone was 
considered. New cloning strategies to circumvent these problems have been 
suggested in recent literature (Durantel et al., 2004; Yang et al.’ 2004). Nevertheless, 
HBV genome is placed under a strong but foreign promoter in both cases. In this 
context, it is not suitable for our study because HBV replication is not under the 
endogenous core promoter, which is especially essential for the functional analysis 
of mutation G1613A at core pro/enhll. In addition chimeric HBV genomes may be 
created using those methods. In one case, the vector has already contained a 
redundant copy of HBV sequence and only requires the insertion of different 
full-length HBV genomes (Yang et al., 2004). In another case, both the full-length 
HBV genome and the redundant copy of HBV sequence are amplified from the same 
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clinical sample (Durantel et al., 2004). It may lead to generation of chimeric HBV 
genome at 3’ end because a clinical sample consists of a mixed population of HBV 
variants. This is the quasi-species nature of HBV. As a consequence, re-construction 
into a 1.3-fold HBV genome was determined, though it involved laborious cloning 
steps. 
4.4.2 Replication competency 
Replication competency is another thing to be noted in constructing HBV 
clone. It is affected by 2 major factors, including: 1) introduction of artificial 
mutations by PCR, and 2) the cloning of a naturally occurring replication-defective 
HBV genome (Durantel et al, 2004). Previous report has shown that about 68% of 
the cloned genomes are replication-competent and only about 40% if the clinical 
specimen is from a patient with low level of viremia, since more PCR cycles are 
»» 
required for amplification (Gunther et al., 1998). Results have revealed that random 
introduction of very few mutations can seriously hamper the HBV replication. It is 
due to the high probability of mutations to be located at the P ORF, which covers 
about two-thirds of the whole HBV genome. Thus any change in the amino acids 
may change the conformation or even inactivate the HBV polymerase. For the 
second problem, individual clones isolated from a single patient could have 
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substantial genetic differences due to the aforementioned quasi-species nature. 
Mutations of replication-defective HBV are most likely derived from the 
spontaneous error of HBV polymerase (Durantel et al.’ 2004; Yang et al., 2004). The 
above 2 factors complicates the construction of a replication-competent HBV clone. 
High fidelity DNA polymerase (such as Pfu polymerase) and less PCR cycles were 
used to minimize the chances of PCR errors. Distinguishing between the naturally 
occurring and PCR derived mutations is difficult. One thing that could be done is to 
compare the sequence of a clone with sequences of a substantial virus subpopulation. 
Naturally occurring mutation is likely to be shared by other HBV sequences. 
Insertion and deletion of HBV fragments are seldom PCR derived (Gunther et al., 
1998). Several clones should be picked to increase the chance of obtaining 
replication-competent HBV clone. In this project, it was fortunate that the full-length 
HBV Cs clone was replication-competent because database of patients-derived HBV 





The luciferase assay was initially tested using the well characterized BCP 
mutation. It was validated as a tool for studying HBV promoter. Taken together, 
mutations T2712C and C1165T did not alter the pre-Sl promoter and X pro/enhl 
respectively, while mutation G1613A significantly increases the core pro/enhll. The 
increase even counteracts the reduction in promoter activity attributed by the BCP 
mutation. To further study the functional effect of G1613A，a replicative competent 
HBV clone is needed. Thus far, a 1.3-fold HBV genotype Cs clone has been 




4.6 Future Work 
Whether mutation G1613A can hamper the binding of NREBP to NRE sequence 
will be further investigated by gel mobility shift assay. The 0.4 M NaCl step-eluted 
fraction of nuclear extracts, which contains NREBP (Lo and Ting, 1994), will be 
incubated either wild-type or mutant NRE sequence before addition of labeled probe. 
The protein-DNA complex will then be resolved on non-denaturing polyacrylamide 
gel. If the point mutant can abolish the protein-DNA complex formation, mutant 
NRE will have very little effect in the competition, thus the shifting band will have 
same intensity of the one without prior addition of competitor. 
Southern blot analysis has to be performed once conditions are optimized so as 
to test the replication competency of the 1.3-fold HBV Cs clone. When an infectious 
clone is ready, functional analysis of mutation is possible. Effect of G1613A alone, 
or in combination with BCP mutation, on precore mRNA and pgRNA transcription, 
HBeAg expression and viral replication will be studied. 
The third question to be addressed is whether the increase in core pro/enhll 
activity attributed by G1613A is genotype specific. It can be tested by performing 




Alignment of sequences from chronic carriers with the B control consensus 
sequence. The sequence from patient number 1939 is most similar to the consensus 
sequence. It was chosen as the template for X pro/enhl (CCl). 
N t 9 8 0 1 0 3 7 
B GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 9 3 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
14 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCAGCCCCTTTCACGCAATG 
1 8 2 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 0 4 5 GGAAAGTGTGTCAACGAATTGTAGGTCTTTTGGGATTTGCTGCTCCTTTCACACAATG 
1 1 2 5 GGAAAGTATGTCAACGAATTGTGGGTCTCTTGGGGTTTGCCGCCCCTTTCACGCAATG 
5 6 4 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 6 5 GGAAAGTATGTCAACGAATTGCGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 9 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
4 8 2 GGAAAGTATGTCAACGAATCGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 4 4 4 GGAAAGTATGTCAACGAATCGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 6 5 GGAAAGTGTGTCAACGAATTGTAGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 7 7 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 5 7 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 2 0 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACACAATG 
1 2 5 2 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGATTTGCCGCCCCTTTCACGCAATG 
1 6 5 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
12 7 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 6 9 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTAGGGTTTGCCGCCCCTTTCACACAATG 
1 9 5 4 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
1 0 7 4 GGAAAGTATGTCAACGAATTGTGGGTCTTTCGGGGTTTGCCGCCCCTTTCACGCAATG 
1 6 8 2 GGAAAGTCTGTCAACGAATTGTGGGTCTCTTGGGGTTTGCTGCCCCTTTCACGCAATG 
5 7 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 9 1 8 GGAAAGTCTGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
8 4 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
9 0 5 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACACAATG 
2 2 6 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
9 6 2 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 0 5 GGAAAGTGTGTCAA.CGAATTGTGGGTCTTTTGGGATTCGCTGCTCCTTTCACACAATG 
7 2 7 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
^ 1 0 0 2 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
“ 2 0 4 0 GGAAAGTGTGTCAACGAATTGTGGGTCTTCTGGGGTTCGCTGCCCCTTTTACACAATG 
7 6 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 9 3 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 02 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
7 0 3 GGAAAGTATGTCAACGAATTGTAGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
8 9 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
4 1 4 GGAAAGTATGTCAACGAATCGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
2 0 2 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACRCAATG 
1 1 7 9 GGAAAGTATGTCAACGGATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 8 7 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
2 4 9 6 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 5 8 5 GGAAAGTATGTCAA.CGAATTGTGGGTCTTTTGGGATTTGCCGCCCCTTTCACGCAATG 
1 9 0 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACACAATG 
1 6 8 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCACCTTTCACACAATG 
1 1 5 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 5 7 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 9 2 6 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
9 4 5 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 2 3 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
9 0 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 1 0 GGAAGGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACACAATG 
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N t l 0 3 8 1 0 9 5 
B TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCRAAACAGGCTTTTACT 
1 9 3 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
14 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 8 2 0 TGGATATCCTGCTTTAATGCCGTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 0 4 5 TGGTTATCCTGCCTTGATGCCTTTATATGCATGTATACAAGCTAAACAGGCTTTTACT 
1 1 2 5 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
5 6 4 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 6 5 TGGCTATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 3 9 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
4 8 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 4 4 4 TGGATATCCTGCTTTAAAGCCTTTATATGCATGTATCCAAGCAAAACAGGCTTTTACT 
1 3 6 5 TGGATATCCTGCTCTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 7 7 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 5 7 8 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTGTT 
1 2 0 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAACAAAACAGGCTTTTACT 
1 2 5 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
1 6 5 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 2 7 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATTCAAGCAAAACAGGCTTTTACT 
1 6 9 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
1 9 5 4 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 0 7 4 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 6 8 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
5 7 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATTCAAGCAAAACAGGCTTTTACT 
1 9 1 8 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
8 4 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
9 0 5 TGGATATCCTGTTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 2 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
9 6 2 TGGATATCCTGCTTTAATGCCTTTATATGCGTGTATACAAGCAAAACAGGCTTTTACT 
1 3 0 5 TGGTTATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
7 2 7 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCCAAACAGGCTTTTACT 
1 0 0 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAGGCAAAACAGGCTTTTACT 
2 0 4 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCTAAACAAGCTTTTACT 
7 6 8 TGGCTATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCTAAACAGGCTTTTACT 
1 9 3 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
“ 1 3 0 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
7 0 3 TGGATATCCTGCTTTAATGCCTTTATACGCATGTATACAAGCAAAACAGGCTTTTACT 
8 9 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
4 1 4 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 0 2 8 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 1 7 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 3 8 7 TGGATATCCTGCTTTAAAGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 4 9 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 5 8 5 TGGATATCCTGCTTTAMTGCCTTTATATGCATGTATACAAGCMAAACAGGCTTTTACT 
1 9 0 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 6 8 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATTCAAGCAAAACAGGCTTTTACC 
1 1 5 8 TGGATATCCTGCTTTAAAGCCTTTATATGCATGTATACAAGCAAAACAAGCTTTTACT 
1 5 7 9 TGGATATCCTGCGTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 9 2 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCCAAACAGGCTTTTACT 
9 4 5 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 2 3 8 TGGATATCCTGCTTTACTGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
9 0 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
1 3 1 0 TGGATATCCTGCTTTAATGCCCTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
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N t l 0 9 6 1 1 5 3 
B TTCTCGCCAACTTACAAGGCCTTTCTRMGTAAMCAGTATCTGAACCTTTACCCCGTTG 
1 9 3 9 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
14 TTCTCGCCAACTTACAAGGCCTTTCTGCGTCAACAGTATCTGAACCTTTACCCCGTTG 
1 8 2 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 0 4 5 TTTTCGCCAACGTATAAGGCCTTTCTAAACAAACAATATCTGAACCTTTACCCCGTTG 
1 1 2 5 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 6 4 TTCTCGCCAACTTACAAGGCCTTTCTCAGTAAACAGTATCTGAACCTTTACCCCGTTG 
2 6 5 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 3 9 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
4 8 2 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 4 4 4 TTCTCGCCAACTTACAAGGCCTTTCTCCGTGAACAGTATCTGACCCTTTACCCCGTTG 
1 3 6 5 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGCACCTTTACCCCGTTG 
1 7 7 9 TTCTCGCCAACTTACAAGGCCTTTCTACGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 5 7 8 TTCTCGCCAACTTACAAGGCCTTTCTACGTCAACAGTATTTGACCCTTTACCCCGTTG 
1 2 0 0 TTCTCGCCAACTTACAAGGCCTTTCTGAGTCAACAATATCTGAACCTTTACCCCGTTG 
1 2 5 2 TTCTCGCCAACTTACAAGGCCTTTCTATGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 6 5 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 2 7 9 TTCTCGCCGACTTATAAGGCCTTTCTAAGTAAACAGTATCTGCACCTTTACCCCGTTG 
1 6 9 1 TTTTCGCCAACTTACAAGGCCTTTCTGAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 9 5 4 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 0 7 4 TTCTCGCCAACTTACAAGGCCTTTCTGAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 6 8 2 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 7 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 9 1 8 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
8 4 1 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
9 0 5 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTTAACCTTTACCCCGTTG 
2 2 6 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
9 6 2 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 3 0 5 TTCTCGCCAACGTATAAGGCCTTTCTGAACAAACAATATCTGAACCTTTACCCCGTTG 
7 2 7 TTCTCGCCAACTTACAAAACCTTTCTACGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 0 0 2 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGCACCTTTACCCCGTTG 
2 0 4 0 TTCTCGCCAACTTACAAAACCTTTCTACGTCAACAATATCTGAACCTTTACCCCGTTG 
7 6 8 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
• 1 9 3 0 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
“ 1 3 0 2 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
7 0 3 TTCTCGCCAACTTACAAGGCCTTTCTCCGTCAACAGTATCTGAACCTTTACCCCGTTG 
8 9 9 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
4 1 4 TTCTCGCCAACTTACAAGGCCTTTCTACGTCACCAGTATCTGAACCTTTACCCCGTTG 
2 0 2 8 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
1 1 7 9 TTCTCGCCAACTTACAAGGCCTTTCTCTGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 3 8 7 TTCTCGCCAACTTACAAGGCCTTTCTCCGTCAACAGTATCTGAACCTTTACCCCGTTG 
2 4 9 6 TTCTCGCCAACTTATAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
1 5 8 5 TTCTCGCCAACTTACAAGGCCTTTCTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
1 9 0 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTACCTGAACCTTTACCCCGTTG 
1 6 8 1 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGCACCTTTACCCCGTTG 
1 1 5 8 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 5 7 9 TTCTCGCCAATTTACAAGGCCTTTTTACGCAACCAGTATCTGAACCTTTACCCCGTTG 
1 9 2 6 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
9 4 5 TTCTCGCCAACTTACAAGGCCTTTCTACGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 2 3 8 TTCTCGCCAACTTACAAGGCCTTTCTGAGTAACCAGTATCTGAACCTTTACCCCGTTG 
9 0 1 TTCTCGCCAACTTACAAGGCCTTTCTGCGTCAWCAGTATCTGAACCTTTACCCTGTTG 
1 3 1 0 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
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N t l l 5 4 1 2 1 1 
B CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 3 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
14 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGATGCAACCCCCACTGGTTGGGG 
1 8 2 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 0 4 5 CTCGGCAACGGCCAGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACAGGCTGGGG 
1 1 2 5 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 6 4 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 6 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 9 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
4 8 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 4 4 4 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 6 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTATTTGCTGACGCAACCCCCACTGGTTGGGG 
1 7 7 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 5 7 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 2 0 0 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 2 5 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 6 5 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 2 7 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 6 9 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 5 4 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 0 7 4 CTCGGCAACGGTCTGGTCTGTGCCCAGTGTTTGCTGGCGCAACCCCTACTGGTTGGGG 
1 6 8 2 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACTCCCACTGGTTGGGG 
5 7 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 1 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
8 4 1 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
9 0 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGG 
2 2 6 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
9 6 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 0 5 CTCGGCAACGGCCAGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGG 
7 2 7 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 0 0 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 0 4 0 CTCGGCAACGGCCTGGTCTMTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
7 6 8 CTCGGCAACGGCATGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
^ 1 9 3 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
“ 1 3 0 2 CTCGGCAACGGCCTGGTCTATGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
7 0 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGATGCAACCCCCACTGGTTGGGG 
8 9 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
4 1 4 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGG 
2 0 2 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 1 7 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 8 7 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 4 96 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 5 8 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 0 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 6 8 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 1 5 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 5 7 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 2 6 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
9 4 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 2 3 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
9 0 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 1 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
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N t l 2 1 2 1 2 6 9 
B CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 9 3 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCGCCTCTGCCGATCCAT 
14 CTTGGCCATAGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
1 8 2 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 0 4 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 1 2 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 6 4 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 6 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 3 9 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
4 8 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 4 4 4 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 3 6 5 CTTGGCCATAGGCCATCAGCGCGTGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 7 7 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 5 7 8 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 2 0 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 2 5 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 6 5 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 2 7 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 6 9 1 CTTGGCCATCGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
1 9 5 4 CTTGGCCATCGGCCTTCAGCGCATACGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 0 7 4 CTTGGCCATAGGCCATCAGCGCATGCGTGGAAGCTTTGGGTCTCCTCTGCCGATCCAT 
1 6 8 2 CTTGGCCATTGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 7 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGGGTCTCCTCTGCCGATCCAT 
1 9 1 8 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
8 4 1 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
9 0 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 2 6 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
9 6 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 3 0 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
7 2 7 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 0 0 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 0 4 0 CTTGGCCATAGGCCATCAGCGCATGCGCGGGACCTTTGTGTCTCCTTTACCGATCCAT 
7 6 8 CTTGGCCATAGSCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
• 1 9 3 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
“ 1 3 02 CTTGGCCATAGGCCATCAGCGCATGCGTGGMACCTTTGTGTCTCCTCTGCCGATCCAT 
7 0 3 CTTGGCTATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
8 9 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
4 1 4 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 0 2 8 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCCATCCAT 
1 1 7 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 3 8 7 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 4 9 6 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 5 8 5 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 9 0 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 6 8 1 CTTGGCCATAGGCCATCAGCGCATGCGTGGAGCCTTTGTGTCTCCTCTGCCGATCCAT 
1 1 5 8 CTTGGCCATTGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 5 7 9 CTTGGCCATAGGCCATCAGCGCCTGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
1 9 2 6 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
9 4 5 CTTGGCCATAGGCCATCAGCGCATGCGGGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 2 3 8 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
9 0 1 CTTGGCTATAGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
1 3 1 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCGCTGCCGATCCAT 
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N t l 2 7 0 1 3 2 7 
B ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGRGCAAAACTCATCG 
1 9 3 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
14 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
1 8 2 0 ACTGCGGAACTCCTAGCCGCCTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 0 4 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
1 1 2 5 ACTGCGGAACTCCTAGCAGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
5 6 4 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
2 6 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 3 9 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
4 8 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCRAANCTCATCG 
1 4 4 4 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
1 3 6 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 7 7 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
1 5 7 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 2 0 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATTG 
1 2 5 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATTG 
1 6 5 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 2 7 9 ACTGCGGAGCTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 6 9 1 ACTGCGGAACTCTTAGCAGCTTGTTTTGCTCGCAGCCGGTCTGGAGCAAAACTCATCG 
1 9 5 4 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 0 7 4 ACTGCGGAACTTCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 6 8 2 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAAATCATCG 
5 7 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAGACTCATCG 
1 9 1 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
8 4 1 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
9 0 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCGAAACTCATTG 
2 2 6 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
9 6 2 ACCGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 3 0 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCGAAACTTATCG 
7 2 7 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
1 0 0 2 ACTGCGGAACTCCTAGCCGCTTGCTTTGCTCACAGCAGGTCTGGGGCAAAACTCATCG 
2 0 4 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGAGCAAAACTTATCG 
7 6 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
^ 1 9 3 0 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
' 1 3 0 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAMCTCATCG 
7 0 3 ACTGCGGAACTTCTAGCCGCCTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
8 9 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
4 1 4 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAACACTCATCG 
2 0 2 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 1 7 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 3 8 7 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAACCTCATCG 
2 4 9 6 ACTGCGGAGCTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAACCTCATCG 
1 5 8 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
1 9 0 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 6 8 1 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 1 5 8 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 5 7 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 9 2 6 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGAGCAAAACTCATCG 
9 4 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 2 3 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
9 0 1 ACTGCGGAACTCCTAGCCGCCTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 3 1 0 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
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N t l 3 2 8 1 3 7 3 
B GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCMTTTCC 
1 9 3 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
14 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
1 8 2 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 0 4 5 GGACTGACAATTCTGTCGTCCTTTCCCGCAAATATACATCGTTTCC 
1 1 2 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTCCC 
5 6 4 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
2 6 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 3 9 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
4 8 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 4 4 4 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 3 6 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 7 7 9 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCATTTCC 
1 5 7 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAATATACATCATTTCC 
1 2 0 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTCCC 
1 2 5 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACAT'CCTTTCC 
1 6 5 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 2 7 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAATATACATCATTTCC 
1 6 9 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAATATACATCATTTCC 
1 9 5 4 GGACTGACAATTCTGTCGTGCTTTCCCGCAAGTATACATCATTCCC 
1 0 7 4 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 6 8 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTCCC 
5 7 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 9 1 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
8 4 1 GGACTGACAATTCTGTTGTGCTCTCCCGCAAGTATACATCGTTCCC 
9 0 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACCTCATTTCC 
2 2 6 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTCCC 
9 6 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 3 0 5 GGACTGACAATTCTGTCGTTCTTTCCCGCAAATATACATCGTTTCC 
7 2 7 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 0 0 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCTTTTCC 
2 0 4 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
7 6 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 9 3 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 3 0 2 GGACTGACAATTCYGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
7 0 3 GGACTGACAATTCTGTTGTGCTCTCCCGCAAGTATACATCGTTTCC 
8 9 9 GGACTGACAACTCTGTCGTGCTCTCCCGCAAGTACACCTCCTTTCC 
4 1 4 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
2 0 2 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 1 7 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 3 8 7 GGACTGACAATTCTGTCGTRCTCTCCCGCAAGTATACATCATTTCC 
2 4 96 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCCTTTCC 
1 5 8 5 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCCTTTCC 
1 9 0 0 GGACTGACAATTCAGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 6 8 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 1 5 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 5 7 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 9 2 6 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
9 4 5 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCGTTCCC 
1 2 3 8 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
9 0 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACCTCCTTTCC 
1 3 1 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
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Alignment of sequences from HCC patients with the B HCC consensus sequence. 
The sequence from patient number 14 is most similar to the consensus sequence. It 
was chosen as the template for X pro/enhl (HI). 
N t 9 8 0 1 0 3 7 
BHCC GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
14 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACACAATG 
5 6 GGAAAGTATGTCAACGAATTGTGGGTCTCTTGGGGTTTGCCGCCCCTTTCACACAATG 
2 0 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCTGCCCCTTTCACACAATG 
2 4 2 GGAAGGTGTGTCAACGAATTGTGGGTCTTTTGGGATTTGCTGCTCCTTTCACACAATG 
1 5 GGAAAGTATGTCAACGAATTGTGGGACTTTTGGGCTTTGCCGCCCCTTTCACGCAATG 
5 0 6 GGAAAGTATGCCAACGAATTGTGGGTCTTTTGGGGTTCGCCGCCCCTTTCACGCAATG 
2 6 0 GGAAAGTCTGTCAACGAATTGTGGGTCTTTTGGGGTTTGCAGCCCCTTTCACGCAATG 
5 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 7 3 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTCGCCGCCCCTTTCACGCAATG 
3 8 5 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCYGCCCCTTTCACRCAATG 
5 6 2 GGAAAGTATGTCAACGAATTGTAGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
04 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 5 2 GGAAAGTATGTCAACGGATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 0 0 2 GGAAAGTATGTCAACGAA.TTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
5 1 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
6 0 GGAAAGTATGTCAACGAATTGTGGGTCTGTTGGGGTTTGCCGCCCCTTTCACGCAATG 
4 8 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 3 GGAAAGTATGTCAACGCATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 4 5 GGAAAGTATGTCAACGAATTGTGGGCCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 1 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
1 9 9 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTTACGCAATG 
3 6 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 1 0 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 8 4 GGAAAGTATGTCAAAGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
5 1 2 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
^ 2 9 3 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCACCTTTCACGCAATG 
“ 1 0 0 3 GGAAAGTTTGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 8 7 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
2 1 8 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
0 1 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
4 5 1 GGAAAGTATGTCAACGAATTGTGGGTCTATTGGGGTTTGCCGCCCCTTTCACACAATG 
6 3 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
4 5 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
1 9 1 GGAAAGTATGTCAACGGATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
5 1 5 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTTCCGCCCCTTTCACGCAATG 
0 7 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
3 3 GGAAAGTATGTCAACGAATTGTGGGTCTTTTGGGGTTTGCCGCCCCTTTCACGCAATG 
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N t l 0 3 8 1 0 9 5 
BHCC TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCRAAACAGGCTTTTACT 
14 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
5 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 0 1 TGGATATCCKGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTCACT 
2 4 2 TGGTTATCCTGCTCTGATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
1 5 TGGTTATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
5 0 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 6 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
5 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCCAAACAGGCTTTTACT 
1 7 3 TGGATATCCTGCTTTAATGCCTTTATATGCTTGTATACAGGCAAAACAGGCTTTTACT 
3 8 5 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
5 6 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
04 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCCAAACAGGCTTTTACT 
2 5 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 0 0 2 TGGATATCCTGCTTTAATGCCTTTATATTCATGTATACAAGCAAAACAGGCTTTTACT 
5 1 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
6 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
4 8 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 3 TGGATATCCTGCTTTGATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 4 5 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 1 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 9 9 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCCAAACAGGCTTTTACC 
3 6 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 1 0 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
2 8 4 TGGATATCCTGCTCTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
5 1 2 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
2 9 3 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTCACT 
‘ 1 0 0 3 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 8 7 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
2 1 8 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCTAAACAGGCTTTTACT 
0 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
4 5 1 TGGATATCCTGCTTTAATGCCTTTGTATGCATGTATACACGCAAAACAGGCTTTTACT 
6 3 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCTAAACAGGCTTTTACC 
4 5 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
1 9 1 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCAAAACAGGCTTTTACG 
5 1 5 TGGATATCCTGCTTTAATGCCCTTATATGCATGTATACAAGCAAAACAGGCTTTTACT 
0 7 TGGATATCCTGCTTTAATGCCTTTATATGCATGTATACAAGCGAAACAGGCTTTTACT 
3 3 TGGATATCCTGCTTTAATGCCTTTGTATGCATGTATACAAGCGAAACAGGCTTTTACT 
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N t l 0 9 6 1 1 5 3 
BHCC TTCTCGCCAACTTACAAGGCCTTTCTRMGTMAACAGTATCTGAACCTTTACCCCGTTG 
14 TTCTCGCCAACCTACAAGTCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 6 TTCTCGTCAACTTACAAGGCCTTTCTCCGTACACAATATCTGAACCTTTACCCCGTTG 
2 0 1 TTCTCGCCAACTTACAAGGCCTTTTTGCGTCACCAGTATCTGAACCTTTACCCCGTTG 
24 2 TTCTCGCCAACTTATAAGGCCTTTCTAAACAAACAATATCTGAACCTTTACCCCGTTG 
1 5 TTCTCGCCAACTTACAAGGCCTTTCTGAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 0 6 TTCTCGCCAACTTACAAGGCCTTTCTATGTAAACAGTATCTGAACCTTTACCCCGTTG 
2 6 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGGCAACAGTATCTGCACCTTTACCCCGTTG 
1 7 3 TTCTCGCCAACTTACAAGGCCTTTCTACGTCAACAGTATCTGAACCTTTACCCCGTTG 
3 8 5 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 6 2 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
04 TTCTCGCCAACTTACAAGGCCTTTCTACGTCAACAGTATCTGAACCTTTACCCCGTTG 
2 5 2 TTCTCGCAAACTTACAAGGCCTTCCTGAGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 0 0 2 TTCTCGCCAACTTACAAGGCCTTTCTGAGTAAACAGTATCTCAACCTTTACCCCGTTG 
5 1 9 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
6 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
4 8 0 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATTTGAACCTTTACCCCGTTG 
13 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
2 4 5 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
1 1 1 TTCTCGCCAACTTACAAGGCCTTTCTGCGTCAACAGTATCTGAACCTTTACCCCGTTG 
1 9 9 TTCTCGCCAACTTACAAGACCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
3 6 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
2 1 0 TTCTCGCCAACTTACAAGGCCTTTCTAAGTMAACAGTATCTGAACCTTTACCCCGTTG 
2 8 4 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTACCTGAACCTTTACCCCGTTG 
5 1 2 TTCTCGCCAACTTACAAGGCCTTTCTAAGCAAACAGTATCTGAACCTTTACCCCGTTG 
2 9 3 TTCTCGCCAACTTACAAGGCCTTTCTCAGTAAACAGTATCTGAACCTTTACCCCGTTG 
' 1 0 0 3 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAATACCTGAACCTTTACCCCGTTG 
1 8 7 TTCTCGCCAACTTACAAGGCCTTTCTCAGTAAACAGTATTTGAACCTTTACCCCGTTG 
2 1 8 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
0 1 TTCTCGCCAACTTACAAGGCCTTTCTCCGTCAACAGTATCTGAACCTTTACCCCGTTG 
4 5 1 TTCTCGCCAACTTACAAGGCCTTTTTACGTAACCAGTATCTGAACCTTTACCCCGTTG 
63 TTCTCGCCAACTTACAAGTCCTTTCTGCGTCATCAGTATCTGAACCTTTACCCCGTTG 
4 5 TTCTCGCCAACTTACAAGGCCTTTCTGCGTAAACAGTATCTGAACCTTTACCCCGTTG 
1 9 1 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
5 1 5 TTCTCGCCAACTTACAAGGCCTTTTTAAGTAAACAGTATCTGCACCTTTACCCCGTTG 
0 7 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
3 3 TTCTCGCCAACTTACAAGGCCTTTCTAAGTAAACAGTATCTGAACCTTTACCCCGTTG 
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N t l l 5 4 1 2 1 1 
BHCC CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
14 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 6 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 0 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 4 2 CGCGGCAACGGTCAGGTCTATGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGG 
1 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 0 6 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 6 0 CGCGGCAACGGTCGGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 0 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 7 3 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
3 8 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 6 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
04 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 5 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 0 0 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 1 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
6 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
4 8 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 4 5 CTCGGCAACGGTCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 1 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 9 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
3 6 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 1 0 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 8 4 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 1 2 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
. 2 9 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 0 0 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 8 7 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
2 1 8 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
0 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
4 5 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
6 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
4 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
1 9 1 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
5 1 5 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
0 7 CTCGGCAACGGCCTGGTGTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
3 3 CTCGGCAACGGCCTGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGTTGGGG 
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N t l 2 1 2 1 2 6 9 
BHCC CTTGGCCATAGGCCATCAGCGCATGCGTGGRACCTTTGTGTCTCCTCTGCCGATCCAT 
14 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 6 CTTGGCTATAGGCCATCAGCGCATGCGTGGCACCTTTGTGTCTCCTCTGCCGATCCAT 
2 0 1 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 4 2 CTTGGCCATAGGTAATCAGCGCGTGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
1 5 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGAGTCTCCTCTTCCGATCCAC 
5 0 6 CTTGGCCATAGGCCATCAGCGCGTGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 6 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGT.GTCTCCTCTGCCGATCCAT 
50 CTTGGCCATAGGCCATCAGCGCCTGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 7 3 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCACTGCCGATCCAT 
3 8 5 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 6 2 CTTGGCCATAGGCCATCGGCGCATGCGTGGCACCTTTGTGTCTCCTCTGCCGATCCAT 
04 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 5 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGGGTCTCCTCTGCCGATCCAT 
1 0 0 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 1 9 CTTGGCCATAGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
60 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
4 8 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
13 CTTGGCCATAGGCCATCAGCGCATGCGTGGAGACTTTGTGTCTCCTCTGCCGATCCAT 
2 4 5 CTTGGCCTTGGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 1 1 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 9 9 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
3 6 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 1 0 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCACTGCCGATCCAT 
2 8 4 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAC 
5 1 2 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
• 2 9 3 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 0 0 3 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
1 8 7 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
2 1 8 CTTGGCCATAGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
0 1 CTTGGCCATTGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
4 5 1 CTTGGCCATGGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
63 CTTGGCCATAGGCCATCAGCGCATGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAT 
4 5 CTTGGCCATAGGCCATCAGCGCGTGCGTGGGACCTTTGTGTCTCCTCTGCCGATCCAG 
1 9 1 CTTGGCCATAGGCCATCAGCGCGTGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
5 1 5 CTTGGCCATAGGCCATCAGSGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
07 CTTGGCCATCGGCCATCAGCGCATGCGTGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
3 3 CTTGGCCATAGGCCATCAGCGCATGCGGGGAACCTTTGTGTCTCCTCTGCCGATCCAT 
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1 3 2 7 
BHCC ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCMGGTCTGGGGCRAAACTCATCG 
14 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCGAACCTCATCG 
5 6 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCCAAACTCATCG 
2 0 1 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
2 4 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCCTCG 
1 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
5 0 6 ACTGCGGAACTCCTAGCCGCCTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
2 6 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTTATCG 
5 0 ACTGCGGAACTCCTGGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
1 7 3 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
3 8 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
5 6 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
04 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
2 5 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAGACTCATCG 
1 0 0 2 ACTGCGGAACTTCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
5 1 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
60 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
4 8 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
13 ACTGCGGRACTCCTAGCAGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
2 4 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCGAAACTCATCG 
1 1 1 ACCGCGGAACTCCTAGCTGCTTGTTTTGCTCGCAGCAGGTCTGGGGCTAAACTAATCG 
1 9 9 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAGACTCATCG 
3 6 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGAGCAAAACTCATCG 
2 1 0 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
2 8 4 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
5 1 2 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCCGGTCTGGGGCAAAACTCATCG 
‘ 2 9 3 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
1 0 0 3 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAACCTCATCG 
1 8 7 ACTGCGGAACTCCTAGCGGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
2 1 8 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
0 1 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
4 5 1 ACTGCGGAACTCCTAGCAGCTTGTTTTGCTCGCAGCCGGTCTGGGGCGAAACTCATCG 
63 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
4 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGMAGGTCTGGGGCGAAACTCATCG 
1 9 1 ATTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
5 1 5 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCGAAACTCATCG 
07 ACTGCGGAACTCCTACCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAAACTCATCG 
3 3 ACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGGGCAAAACTCATCG 
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BHCC GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCRTTTCC 
14 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTCCC 
5 6 GGACTGACAATTCTGTCGTGCTCTCCCGCAAATATACATCATTTCC 
2 0 1 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCATTTCC 
2 4 2 GGACTGACAATTCCGTTGTCCTTTCCCGCAAATATACATCGTTTCC 
1 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
5 0 6 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTCCC 
2 6 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
5 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTCCC 
1 7 3 GGACTGACAATTCTGTCGTACTCTCCCGCAAATATACATCGTTCCC 
3 8 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
5 6 2 GGACTGACAATTCTGTTGTGCTCTCCCGCAAGTATACATCGTTTCC 
04 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
2 5 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 0 0 2 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCATTTCC 
5 1 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTACACATCATTTCC 
6 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
4 8 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 3 GGACTGACAATTCTGTCGTGCTCTCCCGCAAATATACATCCTTTCC 
2 4 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 1 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 9 9 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
3 6 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
2 1 0 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
2 8 4 GGACTGACAATTCTGTCGTACTCTCCCGCAAGTATACATCATTTCC 
5 1 2 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
2 9 3 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTACACATCATTTCC 
• 1 0 0 3 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
1 8 7 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
2 1 8 GGACTGACAATTCTGTCGTGCTCTCMCGCAAGTATACATCATTTCC 
0 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACMTCMTTTCC 
4 5 1 GAACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
6 3 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCGTTTCC 
4 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCC 
1 9 1 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
5 1 5 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
0 7 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCC 
3 3 GGACTGACAATTCTGTCGTGCTCTCCCGCAAGTACACCTCCTTTCC 
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Alignment of sequences from chronic carriers with the B control consensus 
sequence. The sequence from patient number 727 is most similar to the consensus 
sequence. It was chosen as the template for pre-S 1 promoter (CC2). 
N t 2 7 0 6 2 7 6 3 
B CCAGAGYATGTAGTTAATCATTACTTCCAGACGMGACATTATTTACACACTCTTTGGA 
7 2 7 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
14 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 8 2 0 CCAGAGCATGTAGTTGATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 0 4 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACATACTCTTTGGA 
1 1 2 5 CCAGAGCATGTAGTTAATCATTATTTCCAGGCGAGACATTATTTACACACTCTTTGGA 
5 6 4 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 6 5 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 9 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
4 8 2 CCAGAGTATGTAGTTGATCATTACTTCCAGACGCGACATTATTTACATACTCTTTGGA 
1 4 4 4 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 6 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACRCGACATTATTTACACACTCTTTGGA 
1 7 7 9 CCAGAGTATGTAGTTGATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 5 7 8 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 2 0 0 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTGCACACTCTTTGGA 
1 2 5 2 CCAGAGTATGTAGTTAATCATTACTTCCAGACACGACATTATTTACACACTCTTTGGA 
1 6 5 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 2 7 9 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
1 6 9 1 CCGGAACATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
1 9 5 4 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
1 0 7 4 CCAGAGTATGTAGTTCATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 6 8 2 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
5 7 0 CCAGAGTATGTAGTTAATCATTACTTTCAGACGCGACATTATTTACACACTCTTTGGA 
1 9 1 8 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
8 4 1 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACATTCTTTGGA 
9 0 5 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTACTTACACACTCTTTGGA 
2 2 6 CCAGAGTATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
9 6 2 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 0 5 CCAGAGCATGTAGTTAATCATTACTTTCAGACCAGACATTATTTACATACTCTTTGGA 
1 9 3 9 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTCTGGA 
. 1 0 0 2 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 0 4 0 CCCAATCATGTAGTTAATCATTACTCCCAGACGAGACATTATTTACATATTCTTTGGA 
7 6 8 CCAGAGCATGTAGTTAACCATTACTTTCAGACGCGACATTATTTACACACTCTTTGGA 
1 9 3 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 0 2 CCAGAGTATGCAGTTAATCATTACTTCCAGACGCGACATTATTTACACACCCTTTGGA 
7 0 3 CCAGAGCATGTAGTTAATCATTATTTCCAGACGCGACATTATTTACACACTCTTTGGA 
8 9 9 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
4 1 4 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 0 2 8 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACGCTCTTTGGA 
1 1 7 9 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 8 7 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 4 9 6 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 5 8 5 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 9 0 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACATTCTTTGGA 
1 6 8 1 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACATTCTTTGGA 
1 1 5 8 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 5 7 9 CCAGAGTATATAGTTAATCATTACTTCCAGACGCGACATTATTTACACATTCTTTGGA 
1 9 2 6 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
9 4 5 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 2 3 8 CCAGAGTATGTAGTTAATCATTACTTCAAGACGCGACATTATTTACACACTCTTTGGA 
9 0 1 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 3 1 0 CCAGAGCATGTGGTTAATCATTACTTCCAGACCAGACATTATTTACACGCTCTTTGGA 
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N t 2 7 6 4 2 8 2 1 
B AGGCGGGKATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
7 2 7 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
14 AGGCAGGAATCTTATATAAAAGAGAGACCACACATAGCGCCTCATATTACGGGTCACC 
1 8 2 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 0 4 5 AGGCGGGTATCTTATATAAAAGAGAGACAACACATAGCGCCTCATTTTGCGGGTCACC 
1 1 2 5 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTACGGGTCACC 
5 6 4 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 6 5 AGGCGGGGATCTTATATAAAAGAGAATCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 3 9 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
4 8 2 AGGCGGGGATCTTATATAAAAGAGAATCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 4 4 4 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 3 6 5 AGGCGGGGATCTTATATAAAAGAGAATCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 7 7 9 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTACGGGTCACC 
1 5 7 8 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTCTGCGGGTCACC 
1 2 0 0 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 2 5 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACCCGTAGCGCCTCATTTTGCGGGTCACC 
1 6 5 0 AGGCGGGGATCTTATATAAACGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 2 7 9 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGTGGGTCACC 
1 6 9 1 AGGCGGGTATCTTATACAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 5 4 AGGCGGGTATCTTATATAAAAGAGACTCCACACGTAGCGCCTCATTTTACGGGGCACC 
1 0 7 4 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 6 8 2 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 7 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 1 8 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
8 4 1 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
9 0 5 AGGCGGGGATTTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 2 6 AGGCGGGGATCTTATATWAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
9 6 2 AGGCGGGGATTTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTTCGGGTCACC 
1 3 0 5 AGGCGGGTATCTTATACAAAAGAGAGACAACACGTAGCGCCTCATTCTGCGGGTCACC 
1 9 3 9 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 0 0 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 0 4 0 AGGCGGGTATCTTATATAAAAGAGAGACAACACGTAGCGCCTCATTTTGCGGGTCACC 
7 6 8 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
“ 1 9 3 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 3 0 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
7 0 3 AGGCGGGGATCTTATATAAAAGAGAGTCCACACATAGCGCCTCATTTTGCGGGTCACC 
8 9 9 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGTGCCTCATTTTGCGGGTCACC 
4 1 4 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 0 2 8 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 1 7 9 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 3 8 7 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 4 9 6 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 5 8 5 AGGCRGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 0 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 6 8 1 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTACGGGTCACC 
1 1 5 8 AGGCGGGGATCTTATATAAAAGAGAGTCCACACATAGCGCCTCATTTTGCGGGTCACC 
1 5 7 9 AGGCGGGGATCTTATATAAAAGAGAGTCTACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 2 6 AGGCAGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
9 4 5 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTYTGCGGGTCACC 
1 2 3 8 AGGCGGGGATCTTATATAAAAGAGAATCCACACGTAGCGCCTCATTTTACGGGTCACC 
9 0 1 AGGCGGGGATATTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 3 1 0 AGGCGGGTATCTTATATAAAAGAGAGTCAACACATAGCGCCTCATTTTTCGGGTCACC 
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N t 2 8 2 2 2 8 7 9 
B ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
7 2 7 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
14 ATATCCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 8 2 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCAAAACCTCGAAAAGG 
1 0 4 5 ATATTCTTGGGAACAAGAGCTACAGCATGGGAGGTCCGTCCTCCAAACCTCGACGAGG 
1 1 2 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
5 6 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 6 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 3 9 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
4 8 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 4 4 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 3 6 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 7 7 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 5 7 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGACAAGG 
1 2 0 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 2 5 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 6 5 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 2 7 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 6 9 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 9 5 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
‘ 1 0 7 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 6 8 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
5 7 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 9 1 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
8 4 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
9 0 5 ATATTCGTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 2 6 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
9 6 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 3 0 5 ATATTCTTGGGAACCAGAGCTACAGCATGGGAGGTTGGTCCTCCAAACCTCGAAAAGG 
1 9 3 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 0 0 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 0 4 0 ATATTCTTGGGAACAAGAGCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGACAAGG 
7 6 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
' 1 9 3 0 ATATTCTTGGGAACACGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 3 0 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
7 0 3 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
8 9 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGACAAGG 
4 1 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 0 2 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 1 7 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGACAAGG 
1 3 8 7 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 4 9 6 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTGTGTCTTCCAAACCTCGAAAAGG 
1 5 8 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 9 0 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGCCCGTCTTCCAAACCTCGAARAGG 
1 6 8 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 1 5 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 5 7 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAGAAGG 
1 9 2 6 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
9 4 5 ATATTCTTGGGAACAAGAGCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 2 3 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
9 0 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 3 1 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
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N t 2 8 8 0 2 8 8 7 
B CATGGGGA 
7 2 7 CATGGGGA 
14 CATGGGGA 
1 8 2 0 CATGGGGA 
1 0 4 5 CATGGGGA 
1 1 2 5 CATGGGGA 
5 6 4 CATGGGGA 
2 6 5 CATGGGGA 
1 3 9 0 CATGGGGA 
4 8 2 CATGGGGA 
1 4 4 4 CATGGGGA 
1 3 6 5 CATGGGGA 
1 7 7 9 CATGGGGA 
1 5 7 8 CATGGGGA 
1 2 0 0 CATGGGGA 
1 2 5 2 CATGGGGA 
1 6 5 0 CATGGGGA 
1 2 7 9 CATGGGGA 
1 6 9 1 CATGGGGA 
1 9 5 4 CATGGGGA 
1 0 7 4 CATGGGGA 
1 6 8 2 CATGGGGA 
5 7 0 CATGGGGA 
1 9 1 8 CATGGGGA 
8 4 1 CATGGGGA 
9 0 5 CATGGGGA 
2 2 6 CATGGGGA 
9 6 2 CATGGGGA 
1 3 0 5 CATGGGGA 
1 9 3 9 CATGGGGA 
1 0 0 2 CATGGGGA 
2 0 4 0 CATGGGGA 
7 6 8 CATGGGGA 
1 9 3 0 CATGGGGA 
‘ 1 3 0 2 CATGGGGA 
7 0 3 CATGGGGA 
8 9 9 CATGGGGA 
4 1 4 CATGGGGA 
2 0 2 8 CATGGGGA 
1 1 7 9 CATGGGGA 
1 3 8 7 CATGGGGA 
2 4 9 6 CATGGGGA 
1 5 8 5 CATGGGGA 
1 9 0 0 CATGGGGA 
1 6 8 1 CATGGGGA 
1 1 5 8 CATGGGGA 
1 5 7 9 CATGGGGA 
1 9 2 6 CATGGGGA 
9 4 5 CATGGGGA 
1 2 3 8 CATGGGGA 
9 0 1 CATGGGGA 
1 3 1 0 CATGGGGA 
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Alignment of sequences from HCC patients with the B HCC consensus sequence. 
The sequence from patient number 13 is most similar to the consensus sequence 
(H2). It differs with CC2 by only 1 nucleotide, which is the site of mutation at nt 
2712. 
N t 2 7 0 6 2 7 6 3 
BHCC CCAGAGYATGTAGTTAATCATTACTTCCAGACGMGACATTATTTACACACTCTTTGGA 
13 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
5 6 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTCTGGA 
2 0 1 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACGCTCTTTGGA 
2 4 2 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACATACTCTTTGGA 
1 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
5 0 6 CCAGAGCATGTAGTTAATCATTACTTCCAGACAAGACATTATTTACACACTCTTTGGA 
2 6 0 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
5 0 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
1 7 3 CCAGAGCATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACATTCTTTGGA 
14 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACTCTCTTTGGA 
3 8 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
5 6 2 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
04 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACTCTCTTTGGA 
2 5 2 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 0 0 2 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
5 1 9 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
6 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
4 8 0 CCAGAGTATGTAGTTAATCATTACTTCCAGACGAGACATTATTTACACACTCTTTGGA 
2 4 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 1 1 CCAGAGCATGTAGTTAATCATTTCTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 9 9 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
3 6 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 1 0 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
. 2 8 4 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
5 1 2 CCAGAGTATGTAATTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 9 3 CCAGAGAATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACAAATTCTTTGGA 
1 0 0 3 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACAYTCTTTGGA 
1 8 7 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
2 1 8 CCAGAGGATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
0 1 CCAGAGTATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACATTCTTTGGA 
4 5 1 CCAGAGGATGTAGTCAATCATTACTTCCAGACGCGACATTATTTACACACTCTGTGGA 
63 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
4 5 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
1 9 1 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATCTACACACTCTTTGGA 
5 1 5 CCAGAGTATGTAGTTGATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
0 7 CCAGAGYATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
3 3 CCAGAGCATGTAGTTAATCATTACTTCCAGACGCGACATTATTTACACACTCTTTGGA 
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N t 2 7 6 4 2 8 2 1 
BHCC AGGCGGGRATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
13 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 6 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGTGCCTCATTTTACGGGTCACC 
2 0 1 AGGCAGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 4 2 AGGCGGGTATTTTATATAAAAGAGAGACAACACGTAGCGCCTCATTTTGCGGGTCACC 
1 5 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGAAGCGCCTCATTTTGTGGGTCACC 
5 0 6 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 6 0 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 0 AGGCGGGTATATTGTATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 7 3 AGGCGGGTATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
14 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
3 8 5 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 6 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
04 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGTGCCTCATTTTGCGGGTCACC 
2 5 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 0 0 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 1 9 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
60 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
4 8 0 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 4 5 AGGCGGGGATTTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 9 AGGCGGGGATCTTATATAAACGAGAGTCCACACGTAGCGCCTCATTTTGTGGGTCACC 
3 6 AGGCAGGAATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 1 0 AGGCGGGRATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTAYGGGTCACC 
2 8 4 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
" 5 1 2 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTCTGTGGGTCACC 
2 9 3 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 0 0 3 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 8 7 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
2 1 8 AGGCAGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
0 1 AGGCTGGTATCTTATATAAAAGAGAGTCCACACGTAGTGCCTCATTTTACGGGTCACC 
4 5 1 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
63 AGGCGGGAATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
4 5 AGGCTGGGATATTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
1 9 1 AGGCGGGGATATTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
5 1 5 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
07 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGCGCCTCATTTTGCGGGTCACC 
3 3 AGGCGGGGATCTTATATAAAAGAGAGTCCACACGTAGTGCCTCATTTTGCGGGTCACC 
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2 0 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 4 2 ATATTCTTGGGAACAAGAGCTACAGCATGGGAGGTTGGTCCTCCAAACCTCGAAAAGG 
1 5 ATATTCTTGGGAACAAGAGCTACAKCATGGGAGGTTGGWCTTCCAAACCTCGAAAAGG 
5 0 6 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 6 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
5 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 7 3 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
14 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
3 8 5 ATATTCTTGGGAACAAGATCTACAGCA AACCTCGAAAAGG 
5 6 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
04 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 5 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 0 0 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
5 1 9 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
60 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
4 8 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 4 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 1 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 9 9 ATATTCTTGGGAACACGATCTACAGCATGGGAGGTGTGTCTTCCAAACCTCGAAAAGG 
3 6 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 1 0 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAAMCTCGAAAAGG 
2 8 4 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
“ 5 1 2 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
2 9 3 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 0 0 3 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 8 7 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCAAAACCTCGAAAAGG 
2 1 8 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
0 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
4 5 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
63 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
4 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
1 9 1 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
5 1 5 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTCGGTCTTCCAAACCTCGACAAGG 
07 ATATTCTTGGGAACAAGATCTACAGCAT 
3 3 ATATTCTTGGGAACAAGATCTACAGCATGGGAGGTTGGTCTTCCAAACCTCGAAAAGG 
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2 0 1 CATGGGGA 
2 4 2 CATGGGGA 
1 5 CATGGGGA 
5 0 6 CATGGGGA 
2 6 0 CATGGGGA • 
50 CATGGGGA 
1 7 3 CATGGGGA 
14 CATGGGGA 
3 8 5 CATGGGGA 
5 6 2 CATGGGGA 
04 CATGGGGA 
2 5 2 CATGGGGA 
1 0 0 2 CATGGGGA 
5 1 9 CATGGGGA 
6 0 CATGGGGA 
4 8 0 CATGGGGA 
2 4 5 CATGGGGA 
1 1 1 CATGGGGA 
1 9 9 CATGGGGA 
3 6 CATGGGGA 
2 1 0 CATGGGGA 
2 8 4 CATGGGGA 
. 5 1 2 CATGGGGA 
2 9 3 CATGGGGA 
1 0 0 3 CATGGGGA 
1 8 7 CATGGGGA 
2 1 8 CATGGGGA 
0 1 CATGGGGA 
4 5 1 CATGGGGA 
63 CATGGGGA 
4 5 CATGGGGA 
1 9 1 CATGGGGA 
5 1 5 CATGGGGA 
07 
3 3 CATGGGGA 
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Alignment of sequences from chronic carriers with the Cs Control consensus 
sequence. The sequence from patient number 1644 is most similar to the consensus 
sequence. It was chosen as the template for core pro/enhll (CC3). 
N t l 5 7 5 1 6 3 2 
Cs CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGMC 
1 6 4 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 9 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 1 5 9 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCCTGGAGACCACCGTGAACGCCCGCC 
5 5 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGARACCACCGTGAACGCCCGCC 
9 4 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 3 8 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
3 5 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 4 0 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
8 2 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCTGCC 
1 2 8 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 0 7 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 4 4 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
2 0 3 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 2 4 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGARACCACCGTGAACGCCCGCC 
9 2 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
7 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
2 3 4 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
1 7 3 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
8 7 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
4 5 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
1 0 4 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCAAC 
1 2 0 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
4 2 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACACCCGAC 
5 1 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
“ 1 8 1 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTTGCATGGAGACCACCGTGAACGCCCGAC 
9 6 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCAGAC 
1 1 9 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 2 7 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
4 3 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
9 1 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
8 5 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCTCGAC 
1 6 2 9 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGTCCGCC 
1 5 1 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
5 5 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 6 6 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACACCCGAC 
1 4 7 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
8 8 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
130 
Appendix 
N t l 6 3 3 1 6 9 0 
C s AGGTCTTGCCYAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 6 4 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 9 0 AGGCCTTGCCTAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 1 5 9 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 5 4 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
9 4 7 AGGTCTTGCCTAAGGTCTTACATAAAAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 3 8 6 AGGTCTTGCCTCAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 5 2 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGTACTCTCAGCAATGTCAACGAC 
1 4 0 2 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
8 2 0 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 2 8 5 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 0 7 4 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 4 4 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 0 3 2 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 2 4 8 AGGTCTTGCCTAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
9 2 6 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
7 5 AGGCCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 3 4 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 7 3 3 AAGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAACAATGTCAATGAC 
8 7 0 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 5 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 0 4 8 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAATGAC 
1 2 0 5 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 2 8 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 1 5 AGGCCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
- 1 8 1 4 AAGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
9 6 7 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 1 9 3 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 2 7 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 3 0 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
9 1 0 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGAC 
8 5 8 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 6 2 9 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 5 1 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 5 3 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 6 6 3 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 4 7 6 AGGTCTTGCCTAAGGTCTTACATAAGCGGACTCTTGGACTCTCAGCAATGTCAACGAC 
8 8 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
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N t l 6 9 1 1 7 4 8 
C s CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAARGACTGGGAGGAGTTGGGGGAG 
1 6 4 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 9 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 1 5 9 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGARTTGGGGGAG 
5 5 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
9 4 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
1 3 8 6 CGACCTTGAGGCCTACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
3 52 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 4 0 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
8 2 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 2 8 5 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
2 0 7 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 4 4 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAT 
2 0 3 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 2 4 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGATTTGGGGGAG 
9 2 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
7 5 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 3 4 2 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAG 
1 7 3 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
8 7 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
4 5 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 0 4 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 2 0 5 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
4 2 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
5 1 5 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
“ 1 8 1 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
9 6 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 1 9 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 2 7 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
4 3 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
9 1 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
8 5 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
1 6 2 9 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 5 1 2 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAG 
5 5 3 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAG 
1 6 6 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 4 7 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
8 8 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
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N t l 7 4 9 1 8 0 6 
Cs GAGAYTAGRTTAAWGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 6 4 4 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 9 0 GAGATTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 1 5 9 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 5 4 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
9 4 7 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 3 8 6 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 5 2 GAGATTAGGCTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 4 0 2 GAGATTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
8 2 0 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 2 8 5 GAGACTCGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 0 7 4 GAGATTAGGTTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 4 4 2 GATAAGAGATTAATGATTTATGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 0 3 2 GAGATTAGGTTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 2 4 8 GAGATTAGCTTAATGATCTTTGTACTAGGAGACTGTAGGCATAAATTGTTCTGTTCAC 
9 2 6 GAGATTAGGTTAAWGATCTATGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
7 5 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 3 4 2 GAGAATAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 7 3 3 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
8 7 0 GAGTCTAGGTTAATGATCTATGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 5 4 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 0 4 8 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 2 0 5 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 2 8 GAGATTAGATTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 1 5 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
. 1 8 1 4 GAGATTAGATTAAAGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
9 6 7 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 1 9 3 GAGATTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 2 7 2 GAGATTAGATTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 3 0 GAGATTAGATTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
9 1 0 GAGTTTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
8 5 8 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 6 2 9 GAGATTAGATTAA.TGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 5 1 2 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGTTATAAATTGGTCTGTTCAC 
5 5 3 GAGCTTAGATTAAAGACCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 6 6 3 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 4 7 6 GAGATTAGGTTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
8 8 4 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
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N t l 8 0 7 1 8 1 3 
Cs CAGCACC 
1 6 4 4 CAGCACC 
2 9 0 CAGCACC 
1 1 5 9 CAGCACC 
5 5 4 CAGCACC 
9 4 7 CAGCACC 
1 3 8 6 CAGCACC • 
3 5 2 CAGCACC 
1 4 0 2 CAGCACC 
8 2 0 CAGCACC 
1 2 8 5 CAGCACC 
2 0 7 4 CAGCACC 
1 4 4 2 CAGCACC 
2 0 3 2 CAGCACC 
1 2 4 8 CAGCACC 
9 2 6 CAGCACC 
7 5 CAGCACC 
2 3 4 2 CAGCACC 
1 7 3 3 CAGCACC 
8 7 0 CAGCACC 
4 5 4 CAGCACC 
1 0 4 8 CAGCACC 
1 2 0 5 CAGCACC 
4 2 8 CAGCACC 
5 1 5 CAGCACC 
“ 1 8 1 4 CAGAACC 
9 6 7 CAGCACC 
1 1 9 3 CAGCACC 
1 2 7 2 CAGCACC 
4 3 0 CAGCACC 
9 1 0 CAGCACC 
8 5 8 CAGCACC 
1 6 2 9 CAGCACC 
1 5 1 2 CAGCACC 
5 5 3 CAGCACC 
1 6 6 3 CAGCACC 
1 4 7 6 CAGCACC 
8 8 4 CAGCACC 
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Alignment of sequences from HCC patient with the Cs HCC consensus sequence. 
The sequence from patient number 541 is most similar to the consensus sequence. It 
was chosen as the template for core pro/enhll (H3). 
N t l 5 7 5 1 6 3 2 
CsHCC CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGARACCACCGTGAACGCCCGCC 
5 4 1 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCTTGAACGCCCGCC 
4 9 0 CCGTGTGCACTTCGCTTCACTTCTGCACGTGGCATGGAGACCACCGTGAACGCCCGCC 
4 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
5 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 1 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 1 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCGCCGTGAACGCCCGCC 
2 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 6 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGARACCACCGTGAACGCCCGCC 
4 3 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
3 8 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
2 4 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
4 4 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 9 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 5 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
3 5 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
3 9 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCTGCC 
2 9 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
5 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 6 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCTGCC 
2 1 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
03 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 8 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
3 2 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCACC 
2 4 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCRTGGAAACCACCGTGAACGTCCACC 
3 6 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
‘. 2 5 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
4 2 1 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCACC 
4 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
3 1 CCGTGTGCACTTCGCTTCACCTCTGCACGTTTCATGGAGACCACCGTGAACGCCCAAC 
3 2 2 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCAAC 
1 3 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCAGAC 
1 2 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACACCCGAC 
3 2 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
8 3 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGAC 
1 9 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
5 3 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 9 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
4 9 4 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGTCCGCC 
08 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
4 7 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
4 4 1 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
2 6 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCACC 
3 1 1 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGMC 
2 6 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAAACCACCGTGAACGCCCGCC 
1 7 8 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCGCC 
1 8 0 CCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCACC 
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N t l 6 3 2 1 6 9 0 
CsHCC AGGTCTTGCCYAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 4 1 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 7 AGGCCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 9 0 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 6 AGGCCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 5 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 1 6 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 1 4 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGAC 
2 7 AGGCCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 6 6 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 3 6 AAGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 8 6 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 4 3 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 4 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 9 0 AGATCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 5 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGAC 
3 5 0 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 9 6 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 9 2 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 2 AAGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 6 6 AGGTCTTGCCTAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 1 3 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
0 3 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 8 3 AGGTCTTGCCTAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 2 0 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 4 6 AGGCCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 6 2 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 5 7 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 2 1 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 0 AGGTCTTGCCCAAGGTCTTGCATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 1 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
“ 3 2 2 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 3 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGAC 
1 2 8 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 2 8 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
83 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 9 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
5 3 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 9 6 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 9 4 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
08 AGGTCTTGCCCAAGGTCTTACATAAGCGGACTCTTGGACTCTCAGCAATGTCAACGAC 
4 7 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCGCAGCAATGTCAACGAC 
4 4 1 AAGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCCCAGCAATGTCAACGAC 
2 6 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
3 1 1 AGGCCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
2 6 8 AGGTCTTGCCCAAGGTCTTATATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 7 8 , AGGCCTTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGAC 
1 8 0 AGGTCTTGCCCAAGGTCTTACATAAGAGGACTCTTRGACTCTCAGCAATGTCAACGAC 
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N t l 6 9 1 1 7 4 8 
CsHCC CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAARGACTGGGAGGAGTTGGGGGAG 
5 4 1 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
4 9 0 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAG 
4 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
5 5 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGAGTTGGGGGAG 
1 1 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAT 
2 1 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
2 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
2 6 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
4 3 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
3 8 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
2 4 3 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAGGACTGGGAGGAGTTGGGGGAG 
4 4 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAGGACTGGGAGGAGTTGGGGGAG 
1 9 0 CGACCTTGAGGCATATTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 5 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 5 0 CGACCTTGAGGCATACTTCAAAGACTGTGTGTTTAAAGACTGGGAGGAGTTGGGGGAG 
3 9 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
2 9 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
5 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 6 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACMGACTGGGAGGAGTTGGGGGAG 
2 1 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
0 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACTGACTGGGAGGAGTTGGGGGAG 
1 8 3 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 2 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 4 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 6 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
2 5 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
4 2 1 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
4 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 1 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
- 3 2 2 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 3 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
1 2 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 2 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
83 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 9 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAMAGACTGGGAGGAGTTGGGGGAG 
5 3 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 9 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTACAGACTGGGAGGAGTTGGGGGAG 
4 9 4 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
0 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGAGAGAAGTTGGGGGAG 
4 7 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
4 4 1 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 6 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
3 1 1 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
2 6 8 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 7 8 — CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAG 
1 8 0 CGACCTTGAGGCATACTTCAAAGACTGTGTATTTAAAGACTGGGAGGAGTTGGGGGAA 
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Appendix 
N t l 7 4 9 1 8 0 6 
CsHCC GAGAYTAGRTTAATGATCTTTGTACTRGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 4 1 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 7 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 9 0 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 6 GAGTTTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 5 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 1 6 GAGTCTAGGTTAATGATTTATGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 1 4 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 7 GAGATTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 6 6 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 3 6 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 8 6 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 4 3 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 4 2 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 9 0 GAGAATAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 5 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 5 0 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 9 6 GAGATTAGGTTAATGATCTATGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 9 2 GAGACTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 2 GAGACTAGGTTAAAGATTTATGTAATAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 6 6 GAGATTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 1 3 GAGATTAGGTTAAAGATTTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
0 3 GAGTTTAGATTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 8 3 GAGAGTAGATTAATGATTTATGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 2 0 GAGACTAGATTAATGATTTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 4 6 GAGATTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 6 2 GAGTYTAGATTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 5 7 GAGATTAGATTAAAGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 2 1 GAGATTAGATTGTA-ATCT AGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 0 GAGAATAGATTAATGATCTATGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 1 GAGAATAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
,‘ 3 2 2 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 3 4 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 2 8 GAGACTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
3 2 8 GAGATTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
8 3 GAGATTAGATTAAAGGTCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 9 GAGACTAGATTAAWGYTGTTTGTTTTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
5 3 4 GAGTTTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 9 6 GAGACTAGGTTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 9 4 GAGATTAGATTAATGATCTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
0 8 GAGACTAGGTAATTGATTTTTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 7 GAGACTAGGTTAATGATCTATGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
4 4 1 GAGACTAGATTAATGATTTWTGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 6 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
2 6 8 GAGATTAGGTTAATGATCTTTGTAYTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 7 8 GAGATTAGGTTAATGATCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
1 8 0 .GAGAATAGATTAATGATTTATGTACTGGGAGGCTGTAGGCATAAATTGGTCTGTTCAC 
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Appendix 
N t l 8 0 7 1 8 1 3 
CsHCC CAGCACC 
5 4 1 CAGCACC 
17 CAGCACC 
4 9 0 CAGCACC 
4 6 CAGCACC 
5 5 CAGCACC 
1 1 6 CAGCACC 
2 1 4 CAGCACC 
2 7 CAGCACC 
2 6 6 CAGCACC 
4 3 6 CAGCACC 
3 8 6 CAGCACC 
2 4 3 CAGCACC 
4 4 2 CAGCACC 
1 9 0 CAGCACC 
2 5 CTGCACC 
3 5 0 CAGCACC 
3 9 6 CAGCACC 
2 9 2 CAGCACC 
5 2 CAGCACC 
1 6 6 CAGCACC 
2 1 3 CAGCACC 
03 CAGCACC 
1 8 3 CAGCACC 
3 2 0 CAGCACC 
3 6 2 CAGCACC 
2 5 7 CAGCACC 
4 2 1 CAGCACC 
4 0 CAGCACC 
3 1 CAGCACC 
3 2 2 CAGCACC 
“ 1 3 4 CAGCACC 
1 2 8 CAGCACC 
3 2 8 CAGCACC 
83 CAGCACC 
19 CAGCACC 
5 3 4 CAGCACC 
2 96 CAGCACC 
4 9 4 CAGCACC 
08 CAGCACC 
4 7 CAGCACC 
4 4 1 CAGCACC 
2 6 CAGCACC 
3 1 1 CAGCACC 
2 6 8 CAGCACC 
1 7 8 CAGCACC 
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